

BMJ Open

Association of Apolipoprotein B to A-I ratio with diabetes and prediabetes in Chinese subjects: a stratified random sampling based cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-014038
Article Type:	Research
Date Submitted by the Author:	25-Aug-2016
Complete List of Authors:	Zheng, Shuang; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Han, Tingting; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Xu, Hua; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Zhou, Huan; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Ren, Xingxing; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Wu, Peihong; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Zheng, Jun; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Wang, Lihua; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Zhang, Ming; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Jiang, Yihong; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Chen, Yawen; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Qiu, Huiying; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Liu, Wei; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Hu, Yaomin; Shanghai Jiaotong University, Department of Endocrinology
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Diabetes and endocrinology, Diagnostics, Evidence based practice, Public health
Keywords:	apolipoprotein B, apolipoprotein A-I, type 2 diabetes, prediabetes, dyslipidemia

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2016-014038 on 20 January 2017. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

1
2
3
4 **Title Page**

5
6 **Association of Apolipoprotein B to A-I ratio with diabetes and**
7
8
9 **prediabetes in Chinese subjects: a stratified random sampling**
10
11 **based cross-sectional study**

12
13
14 Shuang Zheng^{1*}, Tingting Han^{1*}, Hua Xu^{1*}, Huan Zhou¹, Xingxing Ren¹,

15
16
17 Peihong Wu¹, Jun Zheng¹, Lihua Wang¹, Ming Zhang¹, Yihong Jiang¹, Yawen

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
7 Chen¹, Huiying Qiu¹, Wei Liu¹, Yaomin Hu^{1#}

8
9 1 Department of Endocrinology, Renji Hospital, School of Medicine, Shanghai

10 Jiaotong University, Shanghai 200127, China

11
12 * Contributed equally to this work

13 # Corresponding author

14 Yaomin Hu: amin1031@sina.cn

15 Address: Department of Endocrinology, Renji Hospital, School of Medicine,

16 Shanghai Jiaotong University, No.1630 Dongfang Road, Shanghai 200127,

17 China.

1
2
3
4 **1 Abstract**

5
6 **2 Objectives** Apolipoprotein (Apo)B/ApoA-I ratio is a useful predictor of
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
3 cardiovascular risk. However, the association between the ApoB/ApoA-I ratio and the
4 risk of type 2 diabetes mellitus (T2DM) was still obscure. The aim of the study was to
5 investigate the associations between the value of ApoB/ApoA-I ratio and the risk of
6 T2DM, prediabetes in Chinese population and also assess the role of gender in these
7 associations.

8 **8 Participants and Methods** A stratified random sampling design was used in this
9 cross-sectional study including 264 men and 465 women with either normal glucose
10 tolerance (NGT), prediabetes or T2DM. Serum Apo B, Apo A-I and other lipid and
11 glycaemic traits were measured. Pearson's partial correlation and multivariable
12 logistic analysis were used to evaluate the association between ApoB/ApoA-I ratio
13 and the risk of T2DM, prediabetes.

14 **14 Results** The levels of ApoB/ApoA-I ratio were significantly increased across the
15 stage of NGT, prediabetes and T2DM. Women showed higher levels of
16 ApoB/ApoA-I ratio and ApoB than men in prediabetic and T2DM group, but not in
17 NGT group. ApoB/ApoA-I ratio was closely related with TG, TC, HDL-C, LDL-C
18 and other glycaemic traits. Moreover, in women, the risk of diabetes and prediabetes in
19 the top tertile of ApoB/ApoA-I ratio were 5.34- (95%CI: 1.834-15.525) and
20 4.12-fold (95%CI: 1.167-10.512) higher than in the bottom tertile respectively, after
21 adjusting for potential confounding factors. However, the association was disappeared
22 in men after adjusting for other factors.

1 **Conclusions** The level of ApoB/ApoA-I ratio showed a positive association with the
2 risk of diabetes and prediabetes in Chinese women.
3

4 **Strengths and limitations of this study**

- 5 ● This is an in-depth investigation of the association between ApoB/ApoA-I ratio
6 and diabetes or prediabetes in Chinese population.
- 7 ● Stratified random sampling ensured the equal chance for participant enrolment
8 and the validity of results.
- 9 ● Data collection and analysis were supported by trained survey team, which
10 included researchers with differing areas of expertise and backgrounds.
- 11 ● The cross-sectional design may not confirm the causality between ApoB/ApoA-I
12 ratio and diabetes risk.
- 13 ● Potential bias might be existed due to the single-centre design.

14
15 **Keywords:** apolipoprotein B; apolipoprotein A-I; type 2 diabetes; prediabetes;
16 dyslipidemia
17

18 **Introduction**

19 Atherogenic dyslipidemia is a typical lipoprotein abnormality that including high
20 levels of triglyceride (TG) -rich lipoproteins (mainly very low-density
21 lipoprotein[VLDL]), low levels of high-density lipoprotein (HDL) as well as an
22 elevated proportion of small dense low-density lipoprotein (sd-LDL) particles [1]. To

1
2
3
4 1 date, the evaluation of clinical relevance of atherogenic dyslipidemia has been
5
6 2 focused on its role as an effective predictor of cardiovascular disease (CVD) rather
7
8
9 3 than conventional lipid examinations. Apolipoproteins are important structural and
10
11 4 functional proteins in lipoprotein particles, which take part in the transportation of
12
13
14 5 lipids. Considering the circulating levels of apolipoproteins indicate the number of
15
16 6 lipoprotein particles, the level of Apo-B may reflect the total number of potentially
17
18 7 atherogenic particles, as it is contained in each LDL. Besides, the level of ApoA-I
19
20 8 may present the number of HDL particles [2]. Thus, the ratio of apolipoproteins B and
21
22 9 A-I (ApoB/ApoA-I) would be, theoretically, an ideal indicator for the atherogenic
23
24
25 10 lipid disturbances and cardiovascular risk [3 4].
26
27
28
29

30
31 11 It is well established that atherogenic dyslipidemia is associated with T2DM and
32
33 12 high risk of CVD in T2DM patients [5 6]. Moreover, the mortality rate of CVD in
34
35 13 women with diabetes is higher than men [7]. However, the traditional lipid indices
36
37 14 (e.g. elevated TG and decreased HDL) do not show gender difference in patients with
38
39 15 diabetes. Since ApoB/ApoA-I ratio is an outstanding indicator of atherogenic
40
41 16 dyslipidemia and CVD, the role of it in predicting diabetic risk was expected,
42
43 17 particularly its gender effects. Previous studies demonstrated that ApoB/ApoA-I ratio
44
45 18 may be a strong indicator of metabolic syndrome and insulin resistance in certain
46
47 19 population [8-10]. Nevertheless, the associations of ApoB/ApoA-I ratio with T2DM
48
49 20 and prediabetes as well as its gender effects are still poorly clarified, especially in
50
51 21 Chinese population. Additionally, the association between ApoB/ApoA-I ratio and
52
53
54
55
56
57
58
59
60

1 other lipid or glycaemic traits, such as TG, TC, glucose, insulin sensitivity and
2 secretion, remains partially characterized.

3 Therefore, in this observational study, we aimed to evaluate the association
4 between the level of ApoB/ApoA-I ratio and the risk of T2DM, prediabetes in both
5 men and women and also investigate the correlations between the ratio and other lipid
6 and glycaemic traits.

7 8 **Subjects and Methods**

9 **Subjects**

10 Stratified random sampling was performed to select participants from the database
11 of Renji hospital from January 2010 to December 2014. A total of 1538 subjects aged
12 from 18 to 80 years were included. All of them had visited the department of
13 Endocrinology, Renji Hospital, School of Medicine, Shanghai Jiaotong University for
14 a relative health checkup.

15 The exclusion criteria were regular diabetic and/or lipid-lowering medication use, a
16 history of cardiovascular disease, cerebrovascular disease, chronic renal or hepatic
17 failure, cancer, pregnant, hyperthyroidism and hypothyroidism. Subjects with
18 incomplete data were also excluded.

19 Finally, 729 subjects (264 men and 465 women) were involved in the present
20 study. The study was carried out in accordance with the declaration of Helsinki and
21 the study protocol was approved by the Ethical Committee of Renji Hospital, School
22 of Medicine, Shanghai Jiaotong University. Written informed consents were obtained

1
2
3
4 1 from all subjects included in the study.
5
6
7
8
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

3 **Anthropometry measurements**

4 Body height, weight, waist circumference (WC), hip circumference and blood
5 pressure (BP) were measured by trained survey personnel. Body height was measured
6 once with a portable height scale to the nearest 0.1 cm. Weight was measured using a
7 platform digital scale to the nearest 0.1kg. Both height and weight measurements
8 were taken in light clothing without shoes. Waist circumference was recorded as the
9 midpoint circumference between the iliac crest and the lowest rib. Hip circumference
10 was recorded as the largest gluteal circumference. Circumference measurements were
11 taken twice by a single observer and the mean value was reported. Blood pressure was
12 measured twice in each subject on the right arm after five minutes resting in a sitting
13 position, and the mean of two measurements was considered.

15 **Laboratory analysis**

16 All subjects underwent a standard 75g glucose oral glucose tolerance test (OGTT)
17 after an 8-hour overnight fast. Glucose and lipid levels were measured using fully
18 automatic biochemistry analyzer (Hitachi 7600–110 and Hitachi 7020, respectively,
19 Hitachi Co. Tokyo, Japan); Insulin concentration was determined by
20 immunoradiometric assay kit (Dainabot, Tokyo, Japan); Glycated hemoglobin A1c
21 (HbA1c) level was measured by a high-performance liquid chromatography.

22

1 **Definition of T2DM and prediabetes**

2 According to the 1999 World Health Organization criteria [11], diabetes was
3 defined as fasting plasma glucose (FPG) ≥ 7.0 mmol/L and/or 2-h postload plasma
4 glucose (2hPG) ≥ 11.1 mmol/L, prediabetes was defined as FPG between 6.1mmol/L
5 and 7.0mmol/L and/or 2hPG between 7.8mmol/L and 11.1mmol/L.

6 **Calculation**

7 Body mass index (BMI) was defined as the body weight (kg) divided by the
8 square of body height (m^2). Waist to hip ratio (WHR) was calculated as waist
9 circumference (cm) divided by hip circumference (cm). Indices of insulin resistance
10 and insulin secretion were calculated from the OGTT data: homeostasis model
11 assessment for insulin resistance (HOMA-IR) = fasting insulin ($\mu U/ml$) \times fasting
12 glucose (mmol/L) /22.5; homeostasis model assessment for β cell function index
13 (HOMA- β) = $20 \times$ fasting insulin in $\mu U/ml$ / (fasting glucose in mmol/L -3.5).

14 **Statistical analysis**

15 All statistical analyses were performed using SPSS Version 17.0 (SPSS Inc.,
16 Chicago, IL, USA). Continuous data were expressed as median (Interquartile range
17 25-75%) due to the skewed distribution and compared by Kruskal-Wallis H test or
18 Mann–Whitney U test. Adjusted means were calculated and compared with general
19 linear models. Categorical variables were shown as percentages and compared with
20 Chi-square test. A Pearson’s partial correlation analysis was carried out to identify the

1 correlativity between ApoB/ApoA-I ratio and other variables after adjusting for
2 several covariates. Data with skewed distribution were log-transformed before
3 analysis. A multivariable logistic regression model was conducted to test the
4 associations between ApoB/ApoA-I ratio and the risk of prediabetes and diabetes after
5 controlling for potential confounding factors. The odds ratios (OR) and 95%
6 confidence intervals (CIs) of tertiles 2 to 3 were calculated and compared by using
7 tertile 1 as the reference. Statistical significance was considered at $p < 0.05$.

8 9 **Results**

10 **Clinical and laboratory characteristics**

11 In the present study, among the 729 eligible participants, 36.2% were men and
12 63.8% were women, with a mean age of 51.2 years. There were 222 subjects (75 men
13 and 147 women) diagnosed as T2DM, 240 (90 men and 150 women) as prediabetes,
14 and 267 (99 men and 168 women) as NGT.

15 The anthropometric and metabolic characteristics of them were presented in Table
16 1. After comparison, it was notable that subjects with T2DM had much higher levels
17 of ApoB/ApoA-I ratio than those with prediabetes and NGT, accompanied by worse
18 glucose and lipid profiles. Moreover, those subjects showed higher levels of blood
19 pressure, BMI and WHR. Besides, subjects with prediabetes had higher levels of
20 ApoB/ApoA-I ratio than those with NGT. The levels of blood pressure, BMI and
21 WHR in prediabetes group were also higher than those with NGT.

22 When men and women were analyzed separately, we found the levels of

1 ApoB/ApoA-I ratio in women were higher than in men both in T2DM and prediabetic
2 group. However, the gender difference in NGT group was not significant. Additionally,
3 the level of ApoB in women were also higher than in men in T2DM and prediabetes
4 group. But other lipid indices including TG, TC and LDL-C showed little difference
5 between men and women.

6

7 **Correlations between ApoB/ApoA-I ratio and other variables**

8 After adjusting for age, systolic blood pressure and diastolic blood pressure, the
9 results of Pearson's partial correlation analysis showed that ApoB/ApoA-I ratio was
10 positively correlated with TG, TC, LDL-C and negatively correlated with HDL-C, no
11 matter in NGT, prediabetic and diabetic group (Table 2). Moreover, gender difference
12 was also insignificant. Besides, ApoB/ApoA-I ratio was strongly associated with FPG,
13 HbA1C and HOMA-IR both in men and women. However, the correlations between
14 ApoB/ApoA-I ratio and HOMA- β , insulin levels were not significant.

15

16 **Risk of prediabetes and diabetes according to ApoB/ApoA-I ratio**

17 The level of ApoB/ApoA-I ratio was further divided into tertiles and the first
18 tertile of it was regarded as the reference group. In men, univariate logistic regression
19 analysis showed that the risk of prediabetes in tertile 2 was 2.21-fold higher than in
20 the bottom tertile (OR=2.210, 95%CI:1.121-4.356, $p<0.05$). However, this
21 association was disappeared after adjusting for age, SBP, DBP and TC. In parallel
22 with prediabetes, the association of ApoB/ApoA-I ratio with diabetes was also

1
2
3
4 1 disappeared after adjusting for the aforementioned confounding factors in men (Table
5
6 2 3).

7
8
9 3 Nevertheless, the associations between ApoB/ApoA-I ratio and prediabetes or
10
11 4 diabetes risk in women were much obvious than in men (Table 4). In women,
12
13 5 univariate logistic regression analysis showed that the risk of prediabetes was
14
15 6 increased across the tertile of ApoB/ApoA-I ratio (T2: OR=2.204, 95%CIs:
16
17 7 1.174-3.487, $p<0.01$; T3: OR=4.300, 95%CIs: 2.428-7.615, $p<0.001$). After adjusting
18
19 8 for age, SBP, DBP and BMI, the association between ApoB/ApoA-I ratio and
20
21 9 prediabetes was attenuated but still significant in T3 group (OR=4.123, 95%CIs:
22
23 10 1.167-10.512, $p<0.01$). Moreover, the crude ORs and 95%CIs of diabetes in tertile 2
24
25 11 to 3 were 6.071 (95%CIs: 3.110-11.849, $p<0.001$) and 14.426 (95%CIs: 7.247-28.716,
26
27 12 $p<0.001$), respectively. After further adjusting for TG, TC, HDL-C and LDL-C, the
28
29 13 risk of diabetes in the top tertile of ApoB/ApoA-I ratio was still 5.34-fold higher than
30
31 14 in the bottom tertile (OR=5.335, 95%CIs: 1.834-15.525, $p<0.01$).

15 16 **Prevalence of prediabetes and diabetes according to tertile of ApoB/ApoA-I ratio**

17 As shown in **Fig 1**, the prevalence of prediabetes and T2DM in women were
18 increased in sequence from the bottom to the top tertile of ApoB/ApoA-I ratio (for
19 prediabetes: T1:16.5%, T2:19.8%, T3:25.5%, $p=0.014$; for diabetes, T1:6.2%,
20 T2:22.2%, T3:32.1%, $p<0.001$). However, the prevalence of prediabetes and diabetes
21 in men was higher in T2 than in T1 and T3(for prediabetes: T1:13.2%, T2:14.0%,
22 T3:9.9%, $p>0.05$; for diabetes, T1:7.4%, T2:12.8%, T3:10.7%, $p>0.05$).

1

2 Discussion

3 In the current cross-sectional study, we observed a strong positive association
4 between the level of ApoB/ApoA-I ratio and the risk of prediabetes and diabetes in
5 women, independent of traditional metabolic risk factors. However, the association in
6 men was insignificant after adjusting for potential compounding factors.

7 It is well known that ApoB/ApoA-I ratio is a better predictor of cardiovascular
8 risk than other conventional lipid indices [3 4]. Moreover, emerging evidence
9 indicated that the ratio may be a powerful indicator of metabolic syndrome [10 12] as
10 well as insulin resistance in certain populations [13 14]. However, only a few studies
11 have shown the associations between atherogenic lipoprotein and apolipoprotein
12 levels and the risk of diabetes. Hwang et al.[15] indicated that ApoB/ApoA-I ratio is
13 an effective predictor of T2DM in Korea population. Moreover, the ApoB/LDL-C
14 ratio has been associated with T2DM in a population-based study of Turkish adults
15 [16] and ApoB in the Aboriginal Canadian population [17]. In our study, the results
16 consistently suggested that ApoB/ApoA-I ratio was associated with diabetes and
17 prediabetes in Chinese women.

18 Apolipoproteins regulate the synthesis and metabolism of lipoprotein particles and
19 stabilize their structures additionally. Apolipoprotein B and A-I are the major parts of
20 the protein moieties of LDL-C and HDL-C, respectively. The total level of ApoB
21 reflects the total number of potentially atherogenic particles, as it is present in VLDL,
22 intermediate density lipoprotein, large buoyant LDL, and sd-LDL. Meanwhile,

1
2
3
4 1 ApoA-I plays an important role on removing excess cholesterol from tissues and
5
6 2 incorporating it into HDL for reverse transport to the liver, which was act as
7
8
9 3 atheroprotective particles [18]. Thus, Apo B/Apo A-I ratio reflects the balance of
10
11 4 atherogenic and atheroprotective particles, so the higher the level, the higher the
12
13
14 5 tendency of cholesterol deposition, and consequently the higher the risk of CVD[19].
15

16
17 6 Development of hyperglycemia is closely associated with lipid disturbances [20
18
19 7 21]. In diabetic dyslipidemia, ApoB-containing lipoprotein particles endure
20
21 8 compositional changes, including the formation of sd-LDL and the predominance of
22
23 9 large VLDL (l-VLDL) particles [22-24]. These features were present in up to 50% of
24
25
26
27 10 T2DM patients [25 26] and even occurred in prediabetic patients with insulin
28
29 11 resistance but with normal glucose tolerance [27]. Moreover, this relationship has
30
31 12 been demonstrated by several prospective studies, which indicated that increased
32
33 13 levels of TG, sd-LDL, l-VLDL and small HDL particles are closely associated with
34
35 14 incident diabetes, whereas elevated levels of large HDL particles and Apo A-I are
36
37 15 protective of diabetes [28-30]. In addition, some lipoprotein ratios, which reflect the
38
39 16 proportion of atherogenic and antiatherogenic lipoproteins particles, have also been
40
41 17 suggested as powerful markers of diabetes [15]. In our study, we found the level of
42
43 18 ApoB was significantly increased in subjects with diabetes and prediabetes. However,
44
45 19 the level of ApoA-I showed the opposite trends across the stage of NGT, prediabetes
46
47 20 and diabetes. As a consequence, the ratio of ApoB/ApoA-I was positively associated
48
49 21 with prediabetes and diabetes.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 1 The mechanisms leading to the accumulation of triglyceride-rich lipoproteins
5
6 2 (TRLs) in patients with T2DM have not been fully elucidated. Hogue et al. [31]
7
8
9 3 demonstrated that the elevated apoB-48 containing TRLs of intestinal origin and
10
11 4 apoB-100 containing TRLs of hepatic origin in diabetic subjects are due to the
12
13 5 increased production rates and decreased catabolism of these particles. Furthermore,
14
15 6 Duez et al.[32] showed that intestinal secretion of apoB-48 containing TRLs is
16
17 7 increased in insulin-resistant subjects with hyperinsulinmia. They found that
18
19 8 hyperinsulinmia might enhance the production rate of apoB-48 containing TRLs of
20
21 9 intestinal origin in insulin-resistant people.
22
23
24
25
26
27

28 HDL takes part in the process of reverse cholesterol transportation. Since Apo
29
30 11 A-I is the major protein component of HDL, both HDL and ApoA-I were considered
31
32 12 as protective factors for diabetes. However, one study found that the increased level
33
34 13 of ApoA-I may also enhance the risk of diabetes [33]. This paradoxical result might
35
36 14 be explained by the fact that beneficial HDL can be degenerated to dysfunctional
37
38 15 particles with pro-inflammatory or pro-atherosclerotic property with the help of
39
40 16 glycation and oxidation [34 35]. The lipid and apolipoprotein composition of HDL
41
42 17 was obviously changed and the level of ApoA-I was increased. Thus, the role of
43
44 18 ApoA-I may have two sides in the pathogenesis of diabetes.
45
46
47
48
49
50

51 The effects of gender on lipid and apolipoprotein metabolism have been studied in
52
53 20 several research, but the results were still under discussion. Anahostis et al. [36]
54
55 21 conducted a cross-sectional study in the population of Caucasian premenopausal and
56
57
58
59
60

1 postmenopausal women and men, and they indicated that ApoB concentrations are
2 highest in men but in women rise with age while Apo A-I concentrations are highest
3 in postmenopausal women and lowest in men. Moreover, Li et al. [37] observed that
4 male gender confers decreases in HDL subspecies due to lower levels of ApoA-I;
5 while postmenopausal status results in higher levels of all ApoB-containing
6 lipoproteins. Hence, the risk of CVD was increased in women after menopause. The
7 mechanisms of the gender effects on lipoprotein and apolipoprotein metabolism were
8 not fully elucidated, but may be related to sex hormone changes. Some authors have
9 reported that serum estrone or estradiol levels were positively correlated with HDL-C
10 and TG and inversely associated with TC and LDL-C [38 39]. Moreover, androgen
11 excess in premenopausal women, as is the case in polycystic ovary syndrome (PCOS),
12 has been associated with increased TG and sd-LDL particles, as well as reduced
13 HDL-C [40]. In addition, hyperandrogenemic women demonstrate increased insulin
14 resistance and incidence of CVD [41]. However, there is no denying that the effects
15 of sex hormone on lipid metabolism were still controversial, since some other studies
16 reported conflicting results about the effects of estrone or androgen [42 43]. In our
17 study, it is noticeable that in prediabetic and diabetic group, the levels of ApoB were
18 increased remarkably in women, so was the level of ApoB/ApoA-I ratio. While the
19 concentration of ApoA-I didn't show significant difference between men and women.
20 Additionally, the association between ApoB/ApoA-I ratio and the risk of diabetes was
21 more significant in women than in men, independent of other conventional factors.
22 Unfortunately, in the current study, women were not further divided into

1 premenopausal and postmenopausal groups due to the lack of related information.
2 However, from the median age of women in prediabetic and diabetic groups (56.0
3 years old), we may make an inference that a great number of these women were in the
4 postmenopausal status, which may, to some extent, explain the higher levels of ApoB
5 in women groups and also the higher risk of prediabetes and diabetes in women than
6 men.

7 There were some limitations in our study. First, it was performed using a
8 cross-sectional design and did not control for potential biases from diet, physical
9 activity, smoking and drinking history. Second, women were not further divided
10 according to menopausal status because of the missing information. Thus, a
11 prospective and well- controlled study will be needed to elucidate the association of
12 apoB/ApoA-I ratio with diabetes and prediabetes.

13 In conclusion, our findings indicated a positive association between
14 ApoB/ApoA-I ratio and the risk of prediabetes and diabetes in Chinese women,
15 independent of traditional metabolic risk factors. However, the association in men
16 was insignificant after adjusting for potential confounding factors. Collectively, the
17 results of this study may provide valuable evidence for a better understanding of the
18 role of ApoB/ApoA-I ratio in detecting prediabetes and diabetes in Chinese
19 population, especially in female gender.

21 **Competing interests**

1
2
3
4 1 We declare that we have no conflict of interest.
5
6

7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2 **Financial support**

3 This study was supported by the National Natural Science Foundation of China (No.
4 81270946, 81170758, 30670988) and the Foundation from Renji Hospital, School of
5 Medicine, Shanghai Jiaotong University (RJZZ14-003).

6 **Author contributions**

7 SZ, TH and HX attended the statistical analysis, data interpretation, manuscript
8 writing and revision. HZ, XR, PW, YZ and LW contributed to data interpretation. ME,
9 YJ, YC, HQ and WL contributed to data collection. YH contributed to acquisition of
10 funding, study design, and revision of the paper. All authors revised and approved the
11 final manuscript.

12 **Acknowledgements**

13 The authors thank the staff of the Endocrinology and Metabolism Laboratory and the
14 nursing staff for their dedicated assistance in patient sample collection.
15

16 **Data sharing statement** Additional research data will be made available to the
17 scientific community with as few restrictions as possible.
18

19 **References**

20 1. Christen A, Efstathiadou Z, Laspa E, Johnston DG, Godsland IF. Rate of
21 change and instability in body mass index, insulin resistance, and lipid

- 1 metabolism as predictors of atherosclerotic vascular disease. *J Clin*
2 *Endocrinol Metab* 2007;**92**(10):3780-7 doi:
3 10.1210/jc.2006-2267[published Online First: Epub Date]].
- 4 2. Alfadda AA, Al-Daghri NM, Malabu UH. Apolipoprotein B/apolipoprotein A-I
5 ratio in relation to various definitions of metabolic syndrome among
6 Saudi patients with type 2 diabetes mellitus. *Saudi Med J*
7 2008;**29**(6):821-5
- 8 3. Sniderman AD. Non-HDL cholesterol versus apolipoprotein B in diabetic
9 dyslipoproteinemia: alternatives and surrogates versus the real thing.
10 *Diabetes Care* 2003;**26**(7):2207-8
- 11 4. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk
12 indicators of coronary heart disease and targets for lipid-modifying
13 therapy. *J Intern Med* 2004;**255**(2):188-205
- 14 5. Adiels M, Olofsson SO, Taskinen MR, Boren J. Diabetic dyslipidaemia. *Curr*
15 *Opin Lipidol* 2006;**17**(3):238-46 doi:
16 10.1097/01.mol.0000226115.97436.c0[published Online First: Epub
17 Date]].
- 18 6. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical
19 practice. *Diabetologia* 2003;**46**(6):733-49 doi:
20 10.1007/s00125-003-1111-y[published Online First: Epub Date]].
- 21 7. Legato MJ, Gelzer A, Goland R, et al. Gender-specific care of the patient
22 with diabetes: review and recommendations. *Gend Med*
23 2006;**3**(2):131-58
- 24 8. Solymoss BC, Bourassa MG, Campeau L, et al. Effect of increasing
25 metabolic syndrome score on atherosclerotic risk profile and coronary
26 artery disease angiographic severity. *Am J Cardiol* 2004;**93**(2):159-64
- 27 9. Lind L, Vessby B, Sundstrom J. The apolipoprotein B/AI ratio and the
28 metabolic syndrome independently predict risk for myocardial infarction
29 in middle-aged men. *Arterioscler Thromb Vasc Biol* 2006;**26**(2):406-10
30 doi: 10.1161/01.ATV.0000197827.12431.d0[published Online First:
31 Epub Date]].
- 32 10. Sierra-Johnson J, Somers VK, Kuniyoshi FH, et al. Comparison of
33 apolipoprotein-B/apolipoprotein-AI in subjects with versus without the

- 1
2
3 1 metabolic syndrome. *Am J Cardiol* 2006;**98**(10):1369-73 doi:
4 10.1016/j.amjcard.2006.06.029[published Online First: Epub Date]].
5 2
6 3 11. Colman PG, Thomas DW, Zimmet PZ, Welborn TA, Garcia-Webb P,
7 4
8 Moore MP. New classification and criteria for diagnosis of diabetes
9 5
10 mellitus. The Australasian Working Party on Diagnostic Criteria for
11 6
12 Diabetes Mellitus. *N Z Med J* 1999;**112**(1086):139-41
13 7
14 12. Wallenfeldt K, Bokemark L, Wikstrand J, Hulthe J, Fagerberg B.
15 8
16 Apolipoprotein B/apolipoprotein A-I in relation to the metabolic
17 9
18 syndrome and change in carotid artery intima-media thickness during 3
19 10
20 years in middle-aged men. *Stroke* 2004;**35**(10):2248-52 doi:
21 11
22 10.1161/01.STR.0000140629.65145.3c[published Online First: Epub
23 12
24 Date]].
25 13 13. Sierra-Johnson J, Romero-Corral A, Somers VK, et al. ApoB/apoA-I ratio:
26 14
27 an independent predictor of insulin resistance in US non-diabetic
28 15
29 subjects. *Eur Heart J* 2007;**28**(21):2637-43 doi:
30 16
31 10.1093/eurheartj/ehm360[published Online First: Epub Date]].
32 17 14. Ying X, Qian Y, Jiang Y, Jiang Z, Song Z, Zhao C. Association of the
33 18
34 apolipoprotein B/apolipoprotein A-I ratio and low-density lipoprotein
35 19
36 cholesterol with insulin resistance in a Chinese population with
37 20
38 abdominal obesity. *Acta Diabetol* 2012;**49**(6):465-72 doi:
39 21
40 10.1007/s00592-012-0419-9[published Online First: Epub Date]].
41 22 15. Hwang YC, Ahn HY, Kim WJ, Park CY, Park SW. Increased apoB/A-I ratio
42 23
43 independently associated with Type 2 diabetes mellitus: cross-sectional
44 24
45 study in a Korean population. *Diabet Med* 2012;**29**(9):1165-70 doi:
46 25
47 10.1111/j.1464-5491.2012.03622.x[published Online First: Epub Date]].
48 26 16. Onat A, Can G, Cicek G, Ayhan E, Dogan Y. Predictive value of serum
49 27
50 apolipoprotein B/LDL-cholesterol ratio in cardiometabolic risk:
51 28
52 population-based cohort study. *Clin Biochem* 2010;**43**(18):1381-6 doi:
53 29
54 10.1016/j.clinbiochem.2010.08.027[published Online First: Epub Date]].
55 30 17. Ley SH, Harris SB, Connelly PW, et al. Association of apolipoprotein B with
56 31
57 incident type 2 diabetes in an aboriginal Canadian population. *Clin*
58 32
59 *Chem* 2010;**56**(4):666-70 doi:
60 33
61 10.1373/clinchem.2009.136994[published Online First: Epub Date]].

- 1
2
3 18. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol
4 transport. *J Lipid Res* 1995;**36**(2):211-28
5
6
7 19. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for
8 cardiovascular disease and a target for lipid-lowering therapy--a review
9 of the evidence. *J Intern Med* 2006;**259**(5):493-519 doi:
10 10.1111/j.1365-2796.2006.01643.x[published Online First: Epub Date]].
11
12 20. Zheng S, Zhou H, Han T, et al. Clinical characteristics and beta cell
13 function in Chinese patients with newly diagnosed type 2 diabetes
14 mellitus with different levels of serum triglyceride. *BMC Endocr Disord*
15 2015;**15**:21 doi: 10.1186/s12902-015-0018-1[published Online First:
16 Epub Date]].
17 21. Ren X, Chen ZA, Zheng S, et al. Association between Triglyceride to
18 HDL-C Ratio (TG/HDL-C) and Insulin Resistance in Chinese Patients
19 with Newly Diagnosed Type 2 Diabetes Mellitus. *PLoS One*
20 2016;**11**(4):e0154345 doi: 10.1371/journal.pone.0154345[published
21 Online First: Epub Date]].
22 22. Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM.
23 Lipoprotein particle size and concentration by nuclear magnetic
24 resonance and incident type 2 diabetes in women. *Diabetes*
25 2010;**59**(5):1153-60 doi: 10.2337/db09-1114[published Online First:
26 Epub Date]].
27 23. Austin MA, Mykkanen L, Kuusisto J, et al. Prospective study of small LDLs
28 as a risk factor for non-insulin dependent diabetes mellitus in elderly
29 men and women. *Circulation* 1995;**92**(7):1770-8
30
31 24. Fagot-Campagna A, Knowler WC, Narayan KM, Hanson RL, Saaddine J,
32 Howard BV. HDL cholesterol subfractions and risk of developing type 2
33 diabetes among Pima Indians. *Diabetes Care* 1999;**22**(2):271-4
34
35 25. Abate N, Vega GL, Garg A, Grundy SM. Abnormal cholesterol distribution
36 among lipoprotein fractions in normolipidemic patients with mild NIDDM.
37 *Atherosclerosis* 1995;**118**(1):111-22
38
39 26. Caixas A, Ordonez-Llanos J, de Leiva A, Payes A, Homs R, Perez A.
40 Optimization of glycemic control by insulin therapy decreases the
41 proportion of small dense LDL particles in diabetic patients. *Diabetes*
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1 1997;**46**(7):1207-13
4
5 2 27. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin-resistant
6 3 prediabetic subjects have more atherogenic risk factors than
7 4 insulin-sensitive prediabetic subjects: implications for preventing
8 5 coronary heart disease during the prediabetic state. *Circulation*
9 6 2000;**101**(9):975-80
10 7 28. Mackey RH, Mora S, Bertoni AG, et al. Lipoprotein particles and incident
11 8 type 2 diabetes in the multi-ethnic study of atherosclerosis. *Diabetes*
12 9 *Care* 2015;**38**(4):628-36 doi: 10.2337/dc14-0645[published Online First:
13 10 Epub Date]].
14 11 29. Abbasi A, Corpeleijn E, Gansevoort RT, et al. Role of HDL cholesterol and
15 12 estimates of HDL particle composition in future development of type 2
16 13 diabetes in the general population: the PREVEND study. *J Clin*
17 14 *Endocrinol Metab* 2013;**98**(8):E1352-9 doi:
18 15 10.1210/jc.2013-1680[published Online First: Epub Date]].
19 16 30. Fagot-Campagna A, Narayan KM, Hanson RL, et al. Plasma lipoproteins
20 17 and incidence of non-insulin-dependent diabetes mellitus in Pima
21 18 Indians: protective effect of HDL cholesterol in women. *Atherosclerosis*
22 19 1997;**128**(1):113-9
23 20 31. Hogue JC, Lamarche B, Tremblay AJ, Bergeron J, Gagne C, Couture P.
24 21 Evidence of increased secretion of apolipoprotein B-48-containing
25 22 lipoproteins in subjects with type 2 diabetes. *J Lipid Res*
26 23 2007;**48**(6):1336-42 doi: 10.1194/jlr.M600548-JLR200[published Online
27 24 First: Epub Date]].
28 25 32. Duez H, Lamarche B, Uffelman KD, Valero R, Cohn JS, Lewis GF.
29 26 Hyperinsulinemia is associated with increased production rate of
30 27 intestinal apolipoprotein B-48-containing lipoproteins in humans.
31 28 *Arterioscler Thromb Vasc Biol* 2006;**26**(6):1357-63 doi:
32 29 10.1161/01.ATV.0000222015.76038.14[published Online First: Epub
33 30 Date]].
34 31 33. Onat A, Hergenc G, Bulur S, Ugur M, Kucukdurmaz Z, Can G. The
35 32 paradox of high apolipoprotein A-I levels independently predicting
36 33 incident type-2 diabetes among Turks. *Int J Cardiol* 2010;**142**(1):72-9

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- doi: 10.1016/j.ijcard.2008.12.066[published Online First: Epub Date]].
34. Toth PP, Davidson MH. High-density lipoproteins: marker of cardiovascular risk and therapeutic target. *J Clin Lipidol* 2010;**4**(5):359-64 doi: 10.1016/j.jacl.2010.08.002[published Online First: Epub Date]].
35. Nobecourt E, Tabet F, Lambert G, et al. Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. *Arterioscler Thromb Vasc Biol* 2010;**30**(4):766-72 doi: 10.1161/ATVBAHA.109.201715[published Online First: Epub Date]].
36. Anagnostis P, Stevenson JC, Crook D, Johnston DG, Godsland IF. Effects of gender, age and menopausal status on serum apolipoprotein concentrations. *Clin Endocrinol (Oxf)* 2016 doi: 10.1111/cen.13085[published Online First: Epub Date]].
37. Li Z, McNamara JR, Fruchart JC, et al. Effects of gender and menopausal status on plasma lipoprotein subspecies and particle sizes. *J Lipid Res* 1996;**37**(9):1886-96
38. Kuller LH, Gutai JP, Meilahn E, Matthews KA, Plantinga P. Relationship of endogenous sex steroid hormones to lipids and apoproteins in postmenopausal women. *Arteriosclerosis* 1990;**10**(6):1058-66
39. Soler JT, Folsom AR, Kaye SA, Prineas RJ. Associations of abdominal adiposity, fasting insulin, sex hormone binding globulin, and estrone with lipids and lipoproteins in post-menopausal women. *Atherosclerosis* 1989;**79**(1):21-7
40. Pirwany IR, Fleming R, Greer IA, Packard CJ, Sattar N. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. *Clin Endocrinol (Oxf)* 2001;**54**(4):447-53
41. Rexrode KM, Manson JE, Lee IM, et al. Sex hormone levels and risk of cardiovascular events in postmenopausal women. *Circulation* 2003;**108**(14):1688-93 doi: 10.1161/01.CIR.0000091114.36254.F3[published Online First: Epub Date]].
42. Mudali S, Dobs AS, Ding J, et al. Endogenous postmenopausal hormones and serum lipids: the atherosclerosis risk in communities study. *J Clin*

- 1
2
3 1 Endocrinol Metab 2005;**90**(2):1202-9 doi:
4 10.1210/jc.2004-0744[published Online First: Epub Date]].
5 2
6 43. Bernini GP, Sgro M, Moretti A, et al. Endogenous androgens and carotid
7 intimal-medial thickness in women. J Clin Endocrinol Metab
8 1999;**84**(6):2008-12 doi: 10.1210/jcem.84.6.5824[published Online First:
9 Epub Date]].
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 **Figure legend**

28
29 **Fig 1 Prevalence of prediabetes and diabetes according to tertiles of**

30
31
32 **ApoB/ApoA-I ratio**

33
34 The numbers above the bars mean the prevalence of each outcome, respectively.

35
36
37 T1: tertile 1; T2: tertile 2; T3: tertile 3
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 1 Characteristics of participants according to glucose status and gender

	NGT			Prediabetes			Diabetes			P1	P2	P3
	Total	Men	Women	Total	Men	Women	Total	Men	Women			
Number	267	99	168	240	90	150	222	75	147	NS	NS	NS
Age (years)	51.0 (41.0,57.0)	51.0 (41.5,57.5)	51.0 (40.0,57.0)	56.0 (45.0,61.0)	56.0 (44.0,59.0)	56.0 (47.0,62.0)	56.0 (46.0,60.0)	58.0 (46.0, 61.5)	56.0 (46.0,59.5)	<0.001	<0.001	NS
SBP (mmHg)	114.0 (113.0,116.0)	114.0 (102.0,127.0)	110.0 (102.0,120.5)	121.0 (119.0,123.0)	116.0 (110.0,131.0)	121.0* (114.0,132.0)	121.0 (119.0,123.0)	119.0 (113.0,129.5)	120.0 (110.0,130.5)	<0.001	<0.001	NS
DBP (mmHg)	74.0 (73.0,75.0)	72.0 (68.0,79.0)	74.0 (69.0,80.0)	77.0 (76.0,78.0)	78.0 (72.0,83.0)	78.0 (74.0,82.0)	80.0 (78.0,81.0)	79.0 (73.5,82.0)	79.0 (75.5,85.5)	<0.001	<0.001	0.005
BMI	23.03 (22.60,23.46)	23.11 (21.32,25.15)	23.06 (19.78,24.92)	23.92 (23.47,24.37)	24.12 (21.21,27.46)	23.64 (21.79,26.33)	25.09 (24.61,25.55)	27.67 (24.23,29.45)	23.37** (21.94,26.38)	0.005	<0.001	<0.001
WHR	0.86 (0.85,0.87)	0.88 (0.82,0.91)	0.85* (0.81,0.90)	0.89 (0.88,0.89)	0.89 (0.84,0.93)	0.89 (0.86,0.92)	0.90 (0.90,0.91)	0.91 (0.89,0.94)	0.90* (0.87,0.93)	<0.001	<0.001	0.001
FPG (mmol/L)	4.98 (4.87,5.09)	4.98 (4.65,5.25)	5.01 (4.75,5.35)	5.57 (5.46,5.69)	5.44 (4.92,5.97)	5.60 (5.04,6.11)	7.31 (7.19,7.43)	7.33 (7.16,8.06)	7.15** (5.73,7.87)	<0.001	<0.001	<0.001
2hPG (mmol/L)	6.01 (5.77,6.26)	5.88 (5.30,6.55)	6.05 (5.19,6.83)	9.29 (9.03,9.54)	9.19 (8.51,9.85)	9.36 (8.58,10.19)	13.95 (13.68,14.21)	12.99 (12.23,14.76)	13.07 (11.92,14.73)	<0.001	<0.001	<0.001

FINS	13.73	12.27	11.98	14.70	11.75	12.06	15.38	14.77	14.19	NS	0.014	NS
(μIU/L)	(12.85,14.61)	(9.51,16.90)	(8.76,20.11)	(13.78,15.61)	(10.59,17.71)	(10.74,18.71)	(14.42,16.33)	(10.80,20.03)	(9.82,18.29)			
2hINS	64.18	42.98	55.13	80.05	75.27	71.97	71.23	65.53	63.75*	0.001	NS	NS
(μIU/L)	(57.49,70.87)	(24.02,87.40)	(35.57,71.38)	(73.08,87.02)	(41.60,119.56)	(48.35,103.81)	(63.97,78.49)	(24.57,90.22)	(34.21,110.37)			
HbA1c	5.5	5.5	5.6	5.8	5.8	5.9*	6.9	6.9	6.7	<0.001	<0.001	<0.001
(%)	(5.4,5.6)	(5.2,5.7)	(5.3,5.8)	(5.7,5.9)	(5.5,6.0)	(5.6,6.1)	(6.8,7.0)	(6.6,7.3)	(6.0,7.4)			
HOMA-IR	3.07	2.63	2.67	3.72	2.93	3.28	5.04	4.82	4.18	0.001	<0.001	<0.001
	(2.81,3.33)	(2.01,3.86)	(1.95,4.60)	(3.46,3.99)	(2.27,4.18)	(2.58,4.58)	(4.76,5.32)	(3.46,7.29)	(3.15,5.85)			
HOMA-β	218.63	185.08	161.87	154.67	123.17	122.29	93.41	77.45	74.54	<0.001	<0.001	<0.001
	(203.73,233.53)	(136.51,246.24)	(124.18,257.26)	(139.14,170.19)	(94.47,185.50)	(87.07,186.75)	(77.24,109.58)	(58.17,88.08)	(55.07,112.40)			
TG	1.50	1.23	1.15	1.77	1.50	1.68	2.72	2.55	2.44	0.012	<0.001	<0.001
(mmol/L)	(1.36,1.65)	(0.77,1.70)	(0.77,1.77)	(1.62,1.92)	(1.06,1.99)	(1.09,2.24)	(2.56,2.88)	(1.73,4.14)	(1.69,3.50)			
TC	5.02	4.94	5.02*	5.13	5.15	5.27	5.64	5.47	5.90	NS	<0.001	<0.001
(mmol/L)	(4.92,5.12)	(4.67,5.20)	(4.67,5.40)	(5.03,5.23)	(4.31,5.78)	(4.66,5.55)	(5.53,5.75)	(5.13,6.18)	(4.93,6.29)			
HDL-C	1.48	1.43	1.45	1.34	1.30	1.29	1.23	1.12	1.28*	<0.001	<0.001	<0.001
(mmol/L)	(1.44,1.51)	(1.19,1.69)	(1.24,1.68)	(1.31,1.38)	(1.14,1.48)	(1.15,1.46)	(1.19,1.27)	(1.09,1.28)	(1.07,1.38)			
LDL-C	3.03	2.84	3.12	3.05	2.83	3.08	3.37	3.50	3.36	NS	<0.001	<0.001
(mmol/L)	(2.95,3.12)	(2.58,3.29)	(2.58,3.45)	(2.96,3.14)	(2.60,3.78)	(2.76,3.54)	(3.28,3.47)	(2.88,3.69)	(3.02,4.18)			
ApoA-I	1.48	1.43	1.45	1.39	1.40	1.34	1.33	1.36	1.31	<0.001	<0.001	0.005

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

(g/L)	(1.45,1.51)	(1.31,1.68)	(1.28,1.63)	(1.36,1.43)	(1.26,1.56)	(1.25,1.52)	(1.29,1.36)	(1.22,1.38)	(1.17,1.42)			
ApoB	0.84	0.80	0.84	0.91	0.90	0.97**	0.97	0.97	1.05**	<0.001	<0.001	0.001
(g/L)	(0.81,0.86)	(0.68,0.97)	(0.68,0.97)	(0.88,0.93)	(0.70,0.98)	(0.84,1.03)	(0.94,1.00)	(0.80,1.03)	(0.87,1.17)			
ApoB/Apo	0.60	0.55	0.56	0.67	0.66	0.74**	0.76	0.71	0.78**	<0.001	<0.001	<0.001
A-I ratio	(0.57,0.62)	(0.42,0.72)	(0.44,0.72)	(0.64,0.70)	(0.48,0.77)	(0.56,0.81)	(0.73,0.78)	(0.60,0.82)	(0.68,0.94)			

1 Data were expressed as medians (interquartile ranges 25-75%).

2 SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; WHR: waist to hip ratio; FPG: fasting plasma glucose;

3 2hPG: 2 hour postload plasma glucose; FINS: fasting serum insulin; 2hINS: 2 hour postload serum insulin; HbA1c: glycated hemoglobin A1c;

4 HOMA-IR: homeostatic model assessment of insulin resistance; HOMA-β: homeostatic model assessment of β-cell function; TG: triglyceride;

5 TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; ApoA-I: apolipoprotein A-I;

6 ApoB: apolipoprotein B.

7 P1: NGT versus prediabetic group, P2: NGT versus diabetic group, P3: prediabetic versus diabetic group

8 Comparisons among NGT, prediabetic and diabetic groups were performed after adjusting for age.

1

Table 2 Partial correlation coefficients of ApoB/ApoA-I ratio with lipid profiles and glycometabolism-related traits

	NGT		Prediabetes		Diabetes	
	Men	Women	Men	Women	Men	Women
TG (mmol/L)	0.500 ^{***}	0.474 ^{***}	0.560 ^{***}	0.570 ^{***}	0.503 ^{***}	0.654 ^{***}
TC (mmol/L)	0.410 ^{***}	0.350 ^{***}	0.331 ^{**}	0.271 ^{**}	0.292 [*]	0.648 ^{***}
HDL (mmol/L)	-0.835 ^{***}	-0.727 ^{***}	-0.614 ^{***}	-0.563 ^{***}	-0.337 ^{**}	-0.721 ^{***}
LDL (mmol/L)	0.652 ^{***}	0.597 ^{***}	0.433 ^{***}	0.228 ^{**}	0.427 ^{***}	0.767 ^{***}
FPG (mmol/L)	0.340 ^{**}	0.261 ^{**}	0.432 ^{***}	0.296 ^{***}	0.675 ^{***}	0.471 ^{***}
2hPG (mmol/L)	0.550 ^{***}	0.277 ^{***}	0.198	0.287 ^{***}	0.300 [*]	0.162
FINS (μIU/mL)	0.281 ^{**}	0.195 [*]	0.370 ^{***}	0.122	0.581 ^{***}	0.463 ^{***}
2hINS (μIU/mL)	0.279 ^{**}	0.286 ^{***}	0.696 ^{***}	0.182 [*]	0.109	0.172 [*]
HbA1C (%)	0.253 [*]	0.254 ^{**}	0.274 [*]	0.213 [*]	0.265 [*]	0.278 ^{**}
HOMA-IR	0.326 ^{**}	0.225 ^{**}	0.427 ^{***}	0.175 [*]	0.677 ^{***}	0.584 ^{***}
HOMA-β	-0.007	-0.016	0.014	-0.084	0.208	-0.007

2 Data were analyzed after adjusting for age, SBP and DBP. Variables with skewed
3 distributions were log-transformed before statistical analysis.

4 * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$

5

6

7

8

9

10

11

12

13

Table 3 The risk of prediabetes and Type 2 diabetes according to tertiles of ApoB/ApoA-I ratio in men

		T1	T2	T3
		(0-0.5703)	(0.5704-0.7723)	(≥0.7724)
Prediabetes	n,cases/participants	32/102	34/90	24/72
	Model 1	1	2.210 (1.121, 4.356)*	1.773 (0.857, 3.668)
	Model 2	1	1.673 (0.819, 3.415)	1.251 (0.582, 2.689)
	Model 3	1	1.560 (0.749, 3.251)	1.174 (0.506, 2.727)
Type 2 Diabetes	n,cases/participants	18/102	31/90	26/72
	Model 1	1	3.582 (1.689, 7.596)**	3.414 (1.564, 7.454)**
	Model 2	1	2.615 (1.191, 5.744)*	2.356 (1.041, 5.332)*
	Model 3	1	1.905 (0.841, 4.316)	1.091 (0.433,2.747)

1 Data are odds ratios (OR), 95% confidential intervals (CI).

2 Model 1: unadjusted

3 Model 2: adjusted for age, SBP, DBP

4 Model 3: adjusted for Model 2+ TC

5 * $P<0.05$, ** $P<0.01$, *** $P<0.001$

6

7

8

9

10

11

12

13

14

15

16

Table 4 The risk of prediabetes and Type 2 diabetes according to tertiles of ApoB/ApoA-I ratio in women

		T1	T2	T3
		(0-0.5703)	(0.5704-0.7723)	(≥0.7724)
Prediabetes	n,cases/participants	40/141	48/153	62/171
	Model 1	1	2.024 (1.174, 3.487)**	4.300 (2.428, 7.615)***
	Model 2	1	1.506 (0.835, 2.715)	3.347 (1.810, 6.187)***
	Model 3	1	1.824 (0.863, 3.859)	4.123 (1.617, 10.512)**
Type 2 Diabetes	n,cases/participants	15/141	54/153	78/171
	Model 1	1	6.071 (3.110, 11.849)***	14.426 (7.247, 28.716)***
	Model 2	1	4.772 (2.384, 9.550)***	11.537 (5.619, 23.690)***
	Model 3	1	4.164 (1.720, 10.078)**	5.335 (1.834, 15.525)**

1 Data are odds ratios (OR), 95% confidential intervals (CI).


2 Model 1: unadjusted

3 Model 2: adjusted for age, SBP, DBP, BMI

4 Model 3: adjusted for Model 2+TC, TG, HDL-C, LDL-C

5 * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Prevalence of prediabetes and diabetes according to tertiles of ApoB/ApoA-I ratio
 The numbers above the bars mean the prevalence of each outcome, respectively.
 T1: tertile 1; T2: tertile 2; T3: tertile 3

Fig. 1
 270x87mm (300 x 300 DPI)

Peer review only

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	4
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4-5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4-5
Bias	9	Describe any efforts to address potential sources of bias	4
Study size	10	Explain how the study size was arrived at	4
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5-6
		(b) Describe any methods used to examine subgroups and interactions	5
		(c) Explain how missing data were addressed	5
		(d) If applicable, describe analytical methods taking account of sampling strategy	5
		(e) Describe any sensitivity analyses	6
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6
		(b) Give reasons for non-participation at each stage	6
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	6
		(b) Indicate number of participants with missing data for each variable of interest	6
Outcome data	15*	Report numbers of outcome events or summary measures	6
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	6-7
		(b) Report category boundaries when continuous variables were categorized	7
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	7
Discussion			7
Key results	18	Summarise key results with reference to study objectives	7-8
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10
Generalisability	21	Discuss the generalisability (external validity) of the study results	11
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	11

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Associations of Apolipoprotein B to A-I ratio with diabetes and prediabetes in Chinese subjects: a stratified random sampling based cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-014038.R1
Article Type:	Research
Date Submitted by the Author:	28-Oct-2016
Complete List of Authors:	Zheng, Shuang; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Han, Tingting; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Xu, Hua; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Zhou, Huan; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Ren, Xingxing; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Wu, Peihong; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Zheng, Jun; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Wang, Lihua; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Zhang, Ming; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Jiang, Yihong; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Chen, Yawen; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Qiu, Huiying; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Liu, Wei; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Hu, Yaomin; Shanghai Jiaotong University, Department of Endocrinology
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Diabetes and endocrinology, Diagnostics, Evidence based practice, Public health
Keywords:	apolipoprotein B, apolipoprotein A-I, type 2 diabetes, prediabetes, dyslipidemia

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2016-014038 on 20 January 2017. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Title Page**

2 **Associations of Apolipoprotein B to A-I ratio with diabetes and**
3 **prediabetes in Chinese subjects: a stratified random sampling**
4 **based cross-sectional study**

5 Shuang Zheng^{1*}, Tingting Han^{1*}, Hua Xu^{1*}, Huan Zhou¹, Xingxing Ren¹,
6 Peihong Wu¹, Jun Zheng¹, Lihua Wang¹, Ming Zhang¹, Yihong Jiang¹, Yawen
7 Chen¹, Huiying Qiu¹, Wei Liu¹, Yaomin Hu^{1#}

8
9 1 Department of Endocrinology, Renji Hospital, School of Medicine, Shanghai
10 Jiaotong University, Shanghai 200127, China

11
12 * Contributed equally to this work

13 # Corresponding author

14 Yaomin Hu: amin1031@sina.cn

15 Address: Department of Endocrinology, Renji Hospital, School of Medicine,
16 Shanghai Jiaotong University, No.1630 Dongfang Road, Shanghai 200127,
17 China.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Abstract**

2 **Objectives** Apolipoprotein (Apo)B/ApoA-I ratio is a useful predictor of
3 cardiovascular risk. However, the association between the ApoB/ApoA-I ratio and the
4 risk of type 2 diabetes mellitus (T2DM) was still obscure. The aims of the study were
5 to investigate the associations between the value of ApoB/ApoA-I ratio and the risk of
6 T2DM, prediabetes in Chinese population and also assess the role of gender in these
7 associations.

8 **Participants and Methods** A stratified random sampling design was used in this
9 cross-sectional study including 264 men and 465 women with either normal glucose
10 tolerance (NGT), prediabetes or T2DM. Serum Apo B, Apo A-I and other lipid and
11 glycaemic traits were measured. Pearson's partial correlation and multivariable
12 logistic analysis were used to evaluate the associations between ApoB/ApoA-I ratio
13 and the risk of T2DM, prediabetes.

14 **Results** The levels of ApoB/ApoA-I ratio were significantly increased across the
15 stage of NGT, prediabetes and T2DM. Women showed higher levels of
16 ApoB/ApoA-I ratio and ApoB than men in prediabetic and T2DM groups, but not in
17 NGT group. ApoB/ApoA-I ratio was closely related with TG, TC, HDL-C, LDL-C
18 and other glycaemic traits. Moreover, in women, the risk of diabetes and prediabetes in
19 the top tertile of ApoB/ApoA-I ratio were 3.65- (95% CIs: 1.69-6.10) and 2.19-fold
20 (95% CIs: 1.38-2.84) higher than in the bottom tertile respectively, after adjusting for
21 potential confounding factors. However, the associations were disappeared in men
22 after adjusting for other factors.

1
2
3
4 1 **Conclusions** The level of ApoB/ApoA-I ratio showed positive associations with the
5
6 2 risk of diabetes and prediabetes in Chinese women.
7
8
9 3

10
11 4 **Strengths and limitations of this study**
12

- 13
14 5 ● This is an in-depth investigation of the associations between ApoB/ApoA-I ratio
15
16 6 and diabetes or prediabetes in Chinese population.
17
18 7 ● Stratified random sampling ensured the equal chance for participant enrolment
19
20 8 and the validity of results.
21
22 9 ● Data collection and analysis were supported by trained survey team, which
23
24 10 included researchers with differing areas of expertise and backgrounds.
25
26 11 ● The cross-sectional design may not confirm the causality between ApoB/ApoA-I
27
28 12 ratio and diabetes risk.
29
30 13 ● Potential bias might be existed due to the single-centre design.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

15 **Keywords:** apolipoprotein B; apolipoprotein A-I; type 2 diabetes; prediabetes;
16 dyslipidemia
17
18
19
20
21
22

1 Introduction

2 Atherogenic dyslipidemia is a typical lipoprotein abnormality that including high
3 levels of triglyceride (TG)-rich lipoproteins (mainly very low-density lipoprotein
4 [VLDL]), low levels of high-density lipoprotein (HDL) as well as an elevated
5 proportion of small dense low-density lipoprotein (sd-LDL) particles [1]. To date, the
6 evaluation of clinical relevance of atherogenic dyslipidemia has been focused on its
7 role as an effective predictor of cardiovascular disease (CVD) rather than
8 conventional lipid examinations. Apolipoproteins are important structural and
9 functional proteins in lipoprotein particles, which take part in the transportation of
10 lipids. Given that the circulating levels of apolipoproteins indicate the number of
11 lipoprotein particles, the level of Apo-B may reflect the total number of potentially
12 atherogenic particles, as it is present in VLDL, intermediate density lipoprotein, large
13 buoyant LDL, and sd-LDL. Besides, the level of ApoA-I may present the number of
14 HDL particles [2]. Thus, the ratio of apolipoproteins B and A-I (ApoB/ApoA-I)
15 would be, theoretically, an ideal indicator of atherogenic lipid disturbances and
16 cardiovascular risk [3 4].

17 It is well established that atherogenic dyslipidemia is associated with T2DM and
18 high risk of CVD in T2DM patients [5 6]. Moreover, the mortality rate of CVD in
19 diabetic patients varies with gender [7]. Considering the outstanding performance of
20 ApoB/ApoA-I ratio in indicating atherogenic dyslipidemia and CVD, the role of it in
21 predicting diabetes risk was expected, particularly its gender effects. Previous studies

1 have demonstrated that ApoB/ApoA-I ratio may be a strong marker of metabolic
2 syndrome and insulin resistance in certain population [8-10], but the associations of it
3 with T2DM and prediabetes as well as its gender effects in Chinese population are
4 still poorly clarified. Additionally, the correlations between ApoB/ApoA-I ratio and
5 other lipid or glycaemic traits, such as TG, TC, glucose, insulin sensitivity and
6 secretion, need further investigation.

7 Therefore, in this observational study, we aimed to evaluate the associations
8 between the level of ApoB/ApoA-I ratio and the risk of T2DM, prediabetes in both
9 Chinese men and women and also investigate the correlations between the ratio and
10 other lipid and glycaemic traits.

11

12 **Subjects and Methods**

13 **Subjects**

14 Stratified random sampling was performed to select participants from the database
15 of Renji hospital from January 2010 to December 2014. A total of 1538 subjects aged
16 from 18 to 80 years were included. All of them had visited the department of
17 Endocrinology, Renji Hospital, School of Medicine, Shanghai Jiaotong University for
18 a relative health checkup.

19 The exclusion criteria were regular diabetic and/or lipid-lowering medication use, a
20 history of cardiovascular disease, cerebrovascular disease, chronic renal or hepatic
21 failure, cancer, pregnant, hyperthyroidism and hypothyroidism. Subjects with
22 incomplete data were also excluded.

1
2
3
4 1 Finally, 729 subjects (264 men and 465 women) were involved in the present
5
6 2 study. The study was carried out in accordance with the declaration of Helsinki and
7
8
9 3 the study protocol was approved by the Ethical Committee of Renji Hospital, School
10
11 4 of Medicine, Shanghai Jiaotong University. Written informed consents were obtained
12
13
14 5 from all subjects included in the study.
15
16
17
18
19

20 7 **Anthropometry measurements**

21 8 Body height, weight, waist circumference (WC), hip circumference and blood
22 9 pressure (BP) were measured by trained survey personnel. Body height was measured
23
24 10 once with a portable height scale to the nearest 0.1 cm. Weight was measured using a
25
26
27 11 platform digital scale to the nearest 0.1kg. Both height and weight measurements
28
29 12 were taken in light clothing without shoes. Waist circumference was recorded as the
30
31
32 13 midpoint circumference between the iliac crest and the lowest rib. Hip circumference
33
34 14 was recorded as the largest gluteal circumference. Circumference measurements were
35
36
37 15 taken twice by a single observer and the mean value was reported. Blood pressure was
38
39
40 16 measured twice in each subject on the right arm after five minutes resting in a sitting
41
42
43 17 position, and the mean of two measurements was considered.
44
45
46
47
48
49

50 19 **Laboratory analysis**

51
52 20 All subjects underwent the standard 75g glucose oral glucose tolerance test
53
54
55 21 (OGTT) after an 8-hour overnight fast. Serum ApoB (predominantly ApoB-100) and
56
57
58 22 ApoA-I concentrations were determined by immunoturbidimetric methods using
59
60

1 automatic immunoassay analyzer (Roche E-170, Roche, Basel, Switzerland). Glucose
2 and other lipid levels were measured using fully automatic biochemistry analyzer
3 (Hitachi 7600–110 and Hitachi 7020, respectively, Hitachi Co. Tokyo, Japan); Insulin
4 concentration was determined by immunoradiometric assay kit (Dainabot, Tokyo,
5 Japan); Glycated hemoglobin A1c (HbA1c) level was measured by a
6 high-performance liquid chromatography.

7

8 **Definition of T2DM and prediabetes**

9 According to the 2006 World Health Organization criteria [11], diabetes was
10 defined as fasting plasma glucose (FPG) ≥ 7.0 mmol/L and/or 2-h postload plasma
11 glucose (2hPG) ≥ 11.1 mmol/L, prediabetes was defined as FPG between 6.1 mmol/L
12 and 7.0 mmol/L and/or 2hPG between 7.8 mmol/L and 11.1 mmol/L.

13

14 **Calculation**

15 Body mass index (BMI) was defined as the body weight (kg) divided by the
16 square of body height (m^2). Waist to hip ratio (WHR) was calculated as waist
17 circumference (cm) divided by hip circumference (cm). Indices of insulin resistance
18 and insulin secretion were calculated from the OGTT data: homeostasis model
19 assessment for insulin resistance (HOMA-IR) = fasting insulin ($\mu U/ml$) \times fasting
20 glucose (mmol/L) / 22.5; homeostasis model assessment for β cell function index
21 (HOMA- β) = $20 \times$ fasting insulin in $\mu U/ml$ / (fasting glucose in mmol/L - 3.5).

1

2 **Statistical analysis**

3 All statistical analyses were performed using SPSS Version 17.0 (SPSS Inc.,
4 Chicago, IL, USA). Continuous data were expressed as median (Interquartile range
5 25-75%) due to the skewed distribution and compared by Kruskal-Wallis H test or
6 Mann–Whitney U test. Adjusted means were calculated and compared with general
7 linear models. Categorical variables were shown as percentages and compared with
8 Chi-square test. A Pearson’s partial correlation analysis was carried out to identify the
9 correlativity between ApoB/ApoA-I ratio and other variables after adjusting for
10 several covariates. Data with skewed distribution were log-transformed before
11 analysis. A multivariable logistic regression model was conducted to test the
12 associations between ApoB/ApoA-I ratio and the risk of prediabetes and diabetes after
13 controlling for potential confounding factors. The relative ratios (RR) and 95%
14 confidence intervals (CIs) of tertiles 2 to 3 were calculated and compared by using
15 tertile 1 as reference. RR was calculated based on the formula:
16 $RR=OR/(1-P_0+P_0*OR)$, where OR was odds ratio and P_0 was the disease incidence
17 in non-exposed group. Statistical significance was considered at $p<0.05$.

18

19 **Results**

20 **Clinical and laboratory characteristics**

21 In the present study, among the 729 eligible participants, 36.2% were men and
22 63.8% were women, with a mean age of 51.2 years. There were 30.5% subjects (10.3%

1 men and 20.2% women) diagnosed as T2DM, 32.9% (12.3% men and 20.6% women)
2 as prediabetes, and 36.6% (13.6% men and 23.0% women) as NGT.

3 The anthropometric and metabolic characteristics of them were presented in Table
4 1. After comparison, it was notable that subjects with T2DM had much higher levels
5 of ApoB/ApoA-I ratio than those with prediabetes and NGT, accompanied by worse
6 glucose and lipid profiles. Moreover, those subjects showed higher levels of blood
7 pressure, BMI and WHR. Besides, subjects with prediabetes had higher levels of
8 ApoB/ApoA-I ratio than those with NGT. The levels of blood pressure, BMI and
9 WHR in prediabetic group were also higher than those with NGT.

10 When men and women were analysed separately, we found the levels of
11 ApoB/ApoA-I ratio in women were higher than in men both in T2DM and prediabetic
12 groups. However, the gender difference in NGT group was not significant.
13 Additionally, the levels of ApoB in women were also higher than in men in both
14 T2DM and prediabetic groups. But other lipid indices including TG, TC and LDL-C
15 showed little difference between men and women.

17 **Correlations between ApoB/ApoA-I ratio and other variables**

18 After adjusting for age, systolic blood pressure and diastolic blood pressure, the
19 results of Pearson's partial correlation analysis showed that ApoB/ApoA-I ratio was
20 positively correlated with TG, TC, LDL-C and negatively correlated with HDL-C, no
21 matter in NGT, prediabetic and diabetic groups (Table 2). Moreover, gender
22 difference was also insignificant. Besides, ApoB/ApoA-I ratio was strongly associated

1 with FPG, HbA1C and HOMA-IR both in men and women. However, the correlations
2 between ApoB/ApoA-I ratio and HOMA- β , insulin levels were not significant.

3

4 **Risk of prediabetes and diabetes according to ApoB/ApoA-I ratio**

5 The level of ApoB/ApoA-I ratio was further divided into tertiles and the first
6 tertile of it was regarded as the reference group. In men, the risk of prediabetes in
7 tertile 2 was 1.60-fold higher than in the bottom tertile (RR=1.602,
8 95%CI:1.080-2.122 $p<0.05$). However, this association was disappeared after
9 adjusting for age, SBP, DBP and TC. In parallel with prediabetes, the association of
10 ApoB/ApoA-I ratio with diabetes was also disappeared after adjusting for the
11 aforementioned confounding factors in men (Table 3).

12 Nevertheless, the associations between ApoB/ApoA-I ratio and prediabetes or
13 diabetes risk in women were much obvious than in men (Table 4). In women, the risk
14 of prediabetes was increased across the tertile of ApoB/ApoA-I ratio (T2: RR=1.568,
15 95%CI: 1.119-2.044, $p<0.01$; T3: RR=2.221, 95%CI: 1.728-2.647, $p<0.001$). After
16 adjusting for age, SBP, DBP, BMI and other lipid profiles, the association between
17 ApoB/ApoA-I ratio and prediabetes was attenuated but still significant in T3 group
18 (RR=2.186, 95%CI: 1.376-2.842, $p<0.01$). Moreover, the crude RRs and 95%CI of
19 diabetes in tertile 2 to 3 were 3.943 (95%CI: 2.540-5.500, $p<0.001$) and 5.940
20 (95%CI: 4.353-7.272, $p<0.001$), respectively. After further adjusting for confounding
21 factors, the risk of diabetes in the top tertile of ApoB/ApoA-I ratio was still 3.65-fold
22 higher than in the bottom tertile (RR=3.651, 95%CI: 1.685-6.099, $p<0.01$).

1

2 Prevalence of prediabetes and diabetes according to tertile of ApoB/ApoA-I ratio

3 As shown in **Fig 1**, the prevalence of prediabetes and T2DM in women were
4 increased in sequence from the bottom to the top tertile of ApoB/ApoA-I ratio (for
5 prediabetes: T1:16.5%, T2:19.8%, T3:25.5%, $p=0.014$; for diabetes, T1:6.2%,
6 T2:22.2%, T3:32.1%, $p<0.001$). However, the prevalence of prediabetes and diabetes
7 in men were higher in T2 than in T1 and T3 (for prediabetes: T1:13.2%, T2:14.0%,
8 T3:9.9%, $p>0.05$; for diabetes, T1:7.4%, T2:12.8%, T3:10.7%, $p>0.05$).

9

10 Discussion

11 In the current cross-sectional study, we observed strong positive associations
12 between the level of ApoB/ApoA-I ratio and the risk of prediabetes and diabetes in
13 women, independent of traditional metabolic risk factors. However, the associations
14 in men were insignificant after adjusting for potential compounding factors. Moreover,
15 ApoB/ApoA-I ratio was closely related with other lipid profiles and insulin resistance
16 both in men and women.

17 It is well known that ApoB/ApoA-I ratio is a better predictor of cardiovascular
18 risk than other conventional lipid indices [12]. However, only a few studies have
19 shown the associations between apolipoprotein levels and the risk of diabetes. Hwang
20 et al. [13] indicated that ApoB/ApoA-I ratio is an effective predictor of T2DM in
21 Korea population. Moreover, the ApoB/LDL-C ratio has been associated with T2DM
22 in a population-based study of Turkish adults [14] and ApoB in the Aboriginal

1 Canadian population [15]. Our results consistently suggested that ApoB/ApoA-I ratio
2 was associated with diabetes and prediabetes in Chinese women. Furthermore,
3 ApoB/ApoA-I ratio was closely related with TG, TC, HDL-C, LDL-C, FPG, HbA1C
4 and HOMA-IR, which was in accordance with previous studies [10 16].

5 Apolipoproteins regulate the synthesis and metabolism of lipoprotein particles and
6 stabilize their structures additionally. Hence, there is no doubt that ApoB/ApoA-I ratio
7 was closely related with TG, TC, HDL-C and LDL-C. Apolipoprotein B and A-I are
8 the major parts of the protein moieties of LDL and HDL, respectively. The value of
9 ApoB reflects the number of potentially atherogenic particles [17]. Meanwhile,
10 ApoA-I plays an important role in removing excess cholesterol from tissues and
11 incorporating it into HDL for reverse transport to the liver, which is supposed to stand
12 for atheroprotective particles [18 19]. Thus, ApoB/Apo A-I ratio reflects the balance
13 of atherogenic and atheroprotective particles, so the higher the level, the higher the
14 tendency of cholesterol deposition, and consequently the higher the risk of CVD [20].

15 Development of hyperglycemia is closely associated with lipid disturbances [21
16 22]. In diabetic dyslipidemia, ApoB-containing lipoprotein particles endure
17 compositional changes, including the formation of sd-LDL and the predominance of
18 large VLDL (l-VLDL) particles [23-25]. These features were present in up to 50% of
19 T2DM patients [26 27] and even occurred in prediabetic patients with insulin
20 resistance but normal glucose tolerance [28]. Moreover, this relationship has been
21 demonstrated by several prospective studies, which indicated that increased levels of

1 TG, sd-LDL, l-VLDL and small HDL particles are closely associated with incident
2 diabetes, whereas elevated levels of large HDL particles and Apo A-I are protective of
3 diabetes [29-31]. In our study, we found the levels of ApoB were significantly
4 increased in subjects with diabetes and prediabetes. However, the levels of ApoA-I
5 showed the opposite trends across the stage of NGT, prediabetes and diabetes. As a
6 consequence, the ratio of ApoB/ApoA-I was positively associated with prediabetes
7 and diabetes. Moreover, this ratio was significantly correlated with insulin resistance.
8 Previous studies have demonstrated that the ApoB/ApoA-I ratio is an independent
9 predictor of insulin resistance in both US non-diabetic subjects [32] and Chinese
10 obesity population [33]. A possible explanation for the positive association between
11 the ApoB/ApoA-I ratio and insulin resistance could be that both ApoB and insulin
12 resistance are linked to an inflammatory state [34]. However, detailed mechanisms
13 interpreting this association need further exploration.

14 The mechanisms leading to the accumulation of triglyceride-rich lipoproteins
15 (TRLs) in patients with T2DM have not been fully elucidated. Hogue et al. [35]
16 demonstrated that the elevated apoB-48 containing TRLs of intestinal origin and
17 apoB-100 containing TRLs of hepatic origin in diabetic subjects are due to the
18 increased production rates and decreased catabolism of these particles. Furthermore,
19 Duez et al. [36] showed that intestinal secretion of apoB-48 containing TRLs is
20 increased in insulin-resistant subjects with hyperinsulinemia.

1 HDL takes part in the process of reverse cholesterol transportation. Since Apo
2 A-I is the major protein component of HDL, both HDL and ApoA-I were considered
3 as protective factors for diabetes. However, one study found that the increased level
4 of ApoA-I may also enhance the risk of diabetes [37]. This paradoxical result might
5 be explained by the fact that beneficial HDL can be degenerated to dysfunctional
6 particles with pro-inflammatory or pro-atherosclerotic property with the help of
7 glycation and oxidation [38-40]. The lipid and apolipoprotein composition of HDL
8 was obviously changed and the level of ApoA-I was increased. Thus, the role of
9 ApoA-I may have two sides in the pathogenesis of diabetes.

10 The effects of gender on lipid and apolipoprotein metabolism have been studied in
11 several research, but the results were still under discussion. Anahnostis et al. [41]
12 conducted a cross-sectional study in the population of Caucasian premenopausal and
13 postmenopausal women and men, and they indicated that ApoB concentrations are
14 highest in men but in women rise with age, while Apo A-I concentrations are highest
15 in postmenopausal women and lowest in men. Moreover, Li et al. [42] observed that
16 postmenopausal status results in higher levels of all ApoB-containing lipoproteins.
17 Hence, the risk of CVD was increased in women after menopause. The mechanisms
18 of the gender effects on lipoprotein and apolipoprotein metabolism were not fully
19 revealed, but may be related to sex hormone changes. Some authors have reported
20 that serum estrone or estradiol levels are positively correlated with HDL-C and TG
21 and inversely associated with TC and LDL-C [43 44]. Moreover, androgen excess in

1 premenopausal women, as is the case of polycystic ovary syndrome (PCOS), has been
2 associated with increased TG and sd-LDL particles, as well as reduced HDL-C [45].
3 In addition, hyperandrogenemic women demonstrate increased insulin resistance and
4 incidence of CVD [46]. However, there is no denying that the effects of sex hormone
5 on lipid metabolism were still controversial, since some other studies reported
6 conflicting results about the effects of estrone or androgen [47 48].

7 In our study, it is noticeable that the gender difference was not significant in NGT
8 groups, but in prediabetic and diabetic groups, the levels of ApoB were increased
9 remarkably in women, so were the levels of ApoB/ApoA-I ratio. The results might be
10 interpreted by that age, gender, hormone levels, glucose and lipid metabolism exist in
11 a complicated relative network and the cooperative effects of hormone and glucose
12 status may strengthen the gender difference and worsen the lipid metabolism among
13 prediabetic and diabetic groups. Fortunately, we found the association between
14 ApoB/ApoA-I ratio and the risk of diabetes was still significant in women after
15 adjusting for conventional factors. But it was regret that women were not further
16 divided into premenopausal and postmenopausal groups due to the lack of related
17 information. However, from the median age of women in prediabetic and diabetic
18 groups (56.0 years old), we may make an inference that a great number of these
19 women were in the postmenopausal status, which may, to some extent, explain the
20 higher levels of ApoB in women groups and also the higher risk of prediabetes and
21 diabetes in women. Regarding men, the hormone changes in andropause presented

1
2
3
4 1 progressivity and obvious individual difference, which is not as recognizable as in
5
6 2 menopause [49 50]. Moreover, the risk of diabetes in men derived from various
7
8
9 3 influence factors, such as high working stress, smoking and drinking problems and
10
11 4 lacking of physical exercise. In addition, the number of male participants included in
12
13
14 5 this study was relatively small. Thus, to a certain extent, the aforementioned factors
15
16 6 may explicate the loss of significant association between ApoB/ApoA-I ratio and
17
18
19 7 diabetes risk in men.
20

21
22
23 8 There were some limitations in our study. First, it was performed using a
24
25 9 cross-sectional design and did not control for potential biases from diet, physical
26
27
28 10 activity, smoking and drinking history. Second, women were not further divided
29
30 11 according to menopausal statue because of the missing information. Therefore, a
31
32
33 12 prospective and well- controlled study would be needed to elucidate the associations
34
35 13 of apoB/ApoA-I ratio with diabetes and prediabetes risk.
36
37

38
39 14 In conclusion, our findings indicated positive associations between
40
41 15 ApoB/ApoA-I ratio and the risk of prediabetes and diabetes in Chinese women,
42
43
44 16 independent of traditional metabolic risk factors. However, the associations in men
45
46 17 were insignificant after adjusting for potential compounding factors. Collectively, the
47
48
49 18 results of this study may provide valuable evidence for a better understanding of
50
51 19 ApoB/ApoA-I ratio in detecting prediabetes and diabetes risk in Chinese population,
52
53
54 20 especially in female gender.
55

56
57 21
58
59
60

1
2
3
4 **1 Competing interests**

5
6
7 2 We declare that we have no conflict of interest.
8
9

10
11 **3 Financial support**

12
13
14 4 This study was supported by the National Natural Science Foundation of China (No.
15
16 81270946, 81170758, 30670988) and the Foundation from Renji Hospital, School of
17
18 6 Medicine, Shanghai Jiaotong University (RJZZ14-003).
19

20
21
22
23 **7 Author contributions**

24
25 8 SZ, TH and HX attended the statistical analysis, data interpretation, manuscript
26
27 9 writing and revision. HZ, XR, PW, YZ and LW contributed to data interpretation. ME,
28
29 10 YJ, YC, HQ and WL contributed to data collection. YH contributed to acquisition of
30
31 11 funding, study design, and revision of the paper. All authors revised and approved the
32
33 12 final manuscript.
34
35
36
37
38

39
40 **13 Acknowledgements**

41
42 14 The authors thank the staff of the Endocrinology and Metabolism Laboratory and the
43
44 15 nursing staff for their dedicated assistance in patient sample collection.
45
46
47
48

49
50 **17 Data sharing statement** Additional research data will be made available to the
51
52 18 scientific community with as few restrictions as possible.
53
54
55

56
57 **20 References**
58
59
60

- 1 1. Christen A, Efstathiadou Z, Laspa E, Johnston DG, Godsland IF. Rate of change
2 and instability in body mass index, insulin resistance, and lipid metabolism as
3 predictors of atherosclerotic vascular disease. *J Clin Endocrinol Metab*
4 2007;**92**(10):3780-7 doi: 10.1210/jc.2006-2267[published Online First: Epub
5 Date]].
- 6 2. Alfadda AA, Al-Daghri NM, Malabu UH. Apolipoprotein B/apolipoprotein A-I
7 ratio in relation to various definitions of metabolic syndrome among Saudi
8 patients with type 2 diabetes mellitus. *Saudi Med J* 2008;**29**(6):821-5
- 9 3. Sniderman AD. Non-HDL cholesterol versus apolipoprotein B in diabetic
10 dyslipoproteinemia: alternatives and surrogates versus the real thing. *Diabetes*
11 *Care* 2003;**26**(7):2207-8
- 12 4. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of
13 coronary heart disease and targets for lipid-modifying therapy. *J Intern Med*
14 2004;**255**(2):188-205
- 15 5. Adiels M, Olofsson SO, Taskinen MR, Boren J. Diabetic dyslipidaemia. *Curr Opin*
16 *Lipidol* 2006;**17**(3):238-46 doi:
17 10.1097/01.mol.0000226115.97436.c0[published Online First: Epub Date]].
- 18 6. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice.
19 *Diabetologia* 2003;**46**(6):733-49 doi: 10.1007/s00125-003-1111-y[published
20 Online First: Epub Date]].
- 21 7. Legato MJ, Gelzer A, Goland R, et al. Gender-specific care of the patient with
22 diabetes: review and recommendations. *Gend Med* 2006;**3**(2):131-58
- 23 8. Solymoss BC, Bourassa MG, Campeau L, et al. Effect of increasing metabolic
24 syndrome score on atherosclerotic risk profile and coronary artery disease
25 angiographic severity. *Am J Cardiol* 2004;**93**(2):159-64
- 26 9. Lind L, Vessby B, Sundstrom J. The apolipoprotein B/AI ratio and the metabolic
27 syndrome independently predict risk for myocardial infarction in middle-aged
28 men. *Arterioscler Thromb Vasc Biol* 2006;**26**(2):406-10 doi:
29 10.1161/01.ATV.0000197827.12431.d0[published Online First: Epub Date]].
- 30 10. Sierra-Johnson J, Somers VK, Kuniyoshi FH, et al. Comparison of
31 apolipoprotein-B/apolipoprotein-AI in subjects with versus without the
32 metabolic syndrome. *Am J Cardiol* 2006;**98**(10):1369-73 doi:
33 10.1016/j.amjcard.2006.06.029[published Online First: Epub Date]].

- 1 11. Health Organization and International Diabetes Foundation, Definition and
2 diagnosis of diabetes mellitus and intermediate hyperglycemia: Report of a
3 WHO/IDF consultation. 2006, Geneva: World Health organization.
- 4 12. Montali A, Truglio G, Martino F, et al. Atherogenic dyslipidemia in children:
5 evaluation of clinical, biochemical and genetic aspects. PLoS One
6 2015;**10**(4):e0120099 doi: 10.1371/journal.pone.0120099[published Online
7 First: Epub Date]].
- 8 13. Hwang YC, Ahn HY, Kim WJ, Park CY, Park SW. Increased apoB/A-I ratio
9 independently associated with Type 2 diabetes mellitus: cross-sectional study
10 in a Korean population. Diabet Med 2012;**29**(9):1165-70 doi:
11 10.1111/j.1464-5491.2012.03622.x[published Online First: Epub Date]].
- 12 14. Onat A, Can G, Cicek G, Ayhan E, Dogan Y. Predictive value of serum
13 apolipoprotein B/LDL-cholesterol ratio in cardiometabolic risk:
14 population-based cohort study. Clin Biochem 2010;**43**(18):1381-6 doi:
15 10.1016/j.clinbiochem.2010.08.027[published Online First: Epub Date]].
- 16 15. Ley SH, Harris SB, Connelly PW, et al. Association of apolipoprotein B with
17 incident type 2 diabetes in an aboriginal Canadian population. Clin Chem
18 2010;**56**(4):666-70 doi: 10.1373/clinchem.2009.136994[published Online First:
19 Epub Date]].
- 20 16. Wallenfeldt K, Bokemark L, Wikstrand J, Hulthe J, Fagerberg B. Apolipoprotein
21 B/apolipoprotein A-I in relation to the metabolic syndrome and change in
22 carotid artery intima-media thickness during 3 years in middle-aged men.
23 Stroke 2004;**35**(10):2248-52 doi:
24 10.1161/01.STR.0000140629.65145.3c[published Online First: Epub Date]].
- 25 17. Krychtiuk KA, Kastl SP, Pfaffenberger S, et al. Association of small dense LDL
26 serum levels and circulating monocyte subsets in stable coronary artery
27 disease. PLoS One 2015;**10**(4):e0123367 doi:
28 10.1371/journal.pone.0123367[published Online First: Epub Date]].
- 29 18. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J
30 Lipid Res 1995;**36**(2):211-28
- 31 19. Rosu SA, Rimoldi OJ, Prieto ED, et al. Amyloidogenic propensity of a natural
32 variant of human apolipoprotein A-I: stability and interaction with ligands.
33 PLoS One 2015;**10**(5):e0124946 doi:

- 1
2
3 1 10.1371/journal.pone.0124946[published Online First: Epub Date]].
4
5 2 20. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for
6
7 3 cardiovascular disease and a target for lipid-lowering therapy--a review of the
8
9 4 evidence. *J Intern Med* 2006;**259**(5):493-519 doi:
10
11 5 10.1111/j.1365-2796.2006.01643.x[published Online First: Epub Date]].
12
13 6 21. Zheng S, Zhou H, Han T, et al. Clinical characteristics and beta cell function in
14
15 7 Chinese patients with newly diagnosed type 2 diabetes mellitus with different
16
17 8 levels of serum triglyceride. *BMC Endocr Disord* 2015;**15**:21 doi:
18
19 9 10.1186/s12902-015-0018-1[published Online First: Epub Date]].
20
21 10 22. Ren X, Chen ZA, Zheng S, et al. Association between Triglyceride to HDL-C
22
23 11 Ratio (TG/HDL-C) and Insulin Resistance in Chinese Patients with Newly
24
25 12 Diagnosed Type 2 Diabetes Mellitus. *PLoS One* 2016;**11**(4):e0154345 doi:
26
27 13 10.1371/journal.pone.0154345[published Online First: Epub Date]].
28
29 14 23. Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM. Lipoprotein
30
31 15 particle size and concentration by nuclear magnetic resonance and incident
32
33 16 type 2 diabetes in women. *Diabetes* 2010;**59**(5):1153-60 doi:
34
35 17 10.2337/db09-1114[published Online First: Epub Date]].
36
37 18 24. Austin MA, Mykkanen L, Kuusisto J, et al. Prospective study of small LDLs as a
38
39 19 risk factor for non-insulin dependent diabetes mellitus in elderly men and
40
41 20 women. *Circulation* 1995;**92**(7):1770-8
42
43 21 25. Fagot-Campagna A, Knowler WC, Narayan KM, Hanson RL, Saaddine J, Howard
44
45 22 BV. HDL cholesterol subfractions and risk of developing type 2 diabetes
46
47 23 among Pima Indians. *Diabetes Care* 1999;**22**(2):271-4
48
49 24 26. Abate N, Vega GL, Garg A, Grundy SM. Abnormal cholesterol distribution among
50
51 25 lipoprotein fractions in normolipidemic patients with mild NIDDM.
52
53 26 *Atherosclerosis* 1995;**118**(1):111-22
54
55 27 27. Caixas A, Ordonez-Llanos J, de Leiva A, Payes A, Homs R, Perez A.
56
57 28 Optimization of glycemic control by insulin therapy decreases the proportion
58
59 29 of small dense LDL particles in diabetic patients. *Diabetes*
60
30 1997;**46**(7):1207-13
31
32 31 28. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin-resistant
33
34 32 prediabetic subjects have more atherogenic risk factors than insulin-sensitive
35
36 33 prediabetic subjects: implications for preventing coronary heart disease during

- 1 the prediabetic state. *Circulation* 2000;**101**(9):975-80
- 2 29. Mackey RH, Mora S, Bertoni AG, et al. Lipoprotein particles and incident type 2
3 diabetes in the multi-ethnic study of atherosclerosis. *Diabetes Care*
4 2015;**38**(4):628-36 doi: 10.2337/dc14-0645[published Online First: Epub
5 Date]].
- 6 30. Abbasi A, Corpeleijn E, Gansevoort RT, et al. Role of HDL cholesterol and
7 estimates of HDL particle composition in future development of type 2
8 diabetes in the general population: the PREVEND study. *J Clin Endocrinol*
9 *Metab* 2013;**98**(8):E1352-9 doi: 10.1210/jc.2013-1680[published Online First:
10 Epub Date]].
- 11 31. Fagot-Campagna A, Narayan KM, Hanson RL, et al. Plasma lipoproteins and
12 incidence of non-insulin-dependent diabetes mellitus in Pima Indians:
13 protective effect of HDL cholesterol in women. *Atherosclerosis*
14 1997;**128**(1):113-9
- 15 32. Sierra-Johnson J, Romero-Corral A, Somers VK, et al. ApoB/apoA-I ratio: an
16 independent predictor of insulin resistance in US non-diabetic subjects. *Eur*
17 *Heart J* 2007;**28**(21):2637-43 doi: 10.1093/eurheartj/ehm360[published Online
18 First: Epub Date]].
- 19 33. Ying X, Qian Y, Jiang Y, Jiang Z, Song Z, Zhao C. Association of the
20 apolipoprotein B/apolipoprotein A-I ratio and low-density lipoprotein
21 cholesterol with insulin resistance in a Chinese population with abdominal
22 obesity. *Acta Diabetol* 2012;**49**(6):465-72 doi:
23 10.1007/s00592-012-0419-9[published Online First: Epub Date]].
- 24 34. Sniderman AD, Faraj M. Apolipoprotein B, apolipoprotein A-I, insulin resistance
25 and the metabolic syndrome. *Curr Opin Lipidol* 2007;**18**(6):633-7 doi:
26 10.1097/MOL.0b013e3282f0dd33[published Online First: Epub Date]].
- 27 35. Hogue JC, Lamarche B, Tremblay AJ, Bergeron J, Gagne C, Couture P. Evidence
28 of increased secretion of apolipoprotein B-48-containing lipoproteins in
29 subjects with type 2 diabetes. *J Lipid Res* 2007;**48**(6):1336-42 doi:
30 10.1194/jlr.M600548-JLR200[published Online First: Epub Date]].
- 31 36. Duez H, Lamarche B, Uffelman KD, Valero R, Cohn JS, Lewis GF.
32 Hyperinsulinemia is associated with increased production rate of intestinal
33 apolipoprotein B-48-containing lipoproteins in humans. *Arterioscler Thromb*

- 1
2
3 1 Vasc Biol 2006;**26**(6):1357-63 doi:
4 10.1161/01.ATV.0000222015.76038.14[published Online First: Epub Date]].
5 2
6 37. Onat A, Hergenc G, Bulur S, Ugur M, Kucukdurmaz Z, Can G. The paradox of
7 high apolipoprotein A-I levels independently predicting incident type-2
8 diabetes among Turks. *Int J Cardiol* 2010;**142**(1):72-9 doi:
9 10.1016/j.ijcard.2008.12.066[published Online First: Epub Date]].
10 38. Toth PP, Davidson MH. High-density lipoproteins: marker of cardiovascular risk
11 and therapeutic target. *J Clin Lipidol* 2010;**4**(5):359-64 doi:
12 10.1016/j.jacl.2010.08.002[published Online First: Epub Date]].
13 39. Nobecourt E, Tabet F, Lambert G, et al. Nonenzymatic glycation impairs the
14 antiinflammatory properties of apolipoprotein A-I. *Arterioscler Thromb Vasc*
15 *Biol* 2010;**30**(4):766-72 doi: 10.1161/ATVBAHA.109.201715[published
16 Online First: Epub Date]].
17 40. de Seny D, Cobraiville G, Charlier E, et al. Apolipoprotein-A1 as a
18 damage-associated molecular patterns protein in osteoarthritis: ex vivo and in
19 vitro pro-inflammatory properties. *PLoS One* 2015;**10**(4):e0122904 doi:
20 10.1371/journal.pone.0122904[published Online First: Epub Date]].
21 41. Anagnostis P, Stevenson JC, Crook D, Johnston DG, Godsland IF. Effects of
22 gender, age and menopausal status on serum apolipoprotein concentrations.
23 *Clin Endocrinol (Oxf)* 2016 doi: 10.1111/cen.13085[published Online First:
24 Epub Date]].
25 42. Li Z, McNamara JR, Fruchart JC, et al. Effects of gender and menopausal status
26 on plasma lipoprotein subspecies and particle sizes. *J Lipid Res*
27 1996;**37**(9):1886-96
28 43. Kuller LH, Gutai JP, Meilahn E, Matthews KA, Plantinga P. Relationship of
29 endogenous sex steroid hormones to lipids and apoproteins in postmenopausal
30 women. *Arteriosclerosis* 1990;**10**(6):1058-66
31 44. Soler JT, Folsom AR, Kaye SA, Prineas RJ. Associations of abdominal adiposity,
32 fasting insulin, sex hormone binding globulin, and estrone with lipids and
33 lipoproteins in post-menopausal women. *Atherosclerosis* 1989;**79**(1):21-7
34 45. Pirwany IR, Fleming R, Greer IA, Packard CJ, Sattar N. Lipids and lipoprotein
35 subfractions in women with PCOS: relationship to metabolic and endocrine
36 parameters. *Clin Endocrinol (Oxf)* 2001;**54**(4):447-53

- 1
2
3 46. Rexrode KM, Manson JE, Lee IM, et al. Sex hormone levels and risk of
4 cardiovascular events in postmenopausal women. *Circulation*
5 2003;**108**(14):1688-93 doi: 10.1161/01.CIR.0000091114.36254.F3[published
6 Online First: Epub Date]].
7
8 47. Mudali S, Dobs AS, Ding J, et al. Endogenous postmenopausal hormones and
9 serum lipids: the atherosclerosis risk in communities study. *J Clin Endocrinol*
10 *Metab* 2005;**90**(2):1202-9 doi: 10.1210/jc.2004-0744[published Online First:
11 Epub Date]].
12
13 48. Bernini GP, Sgro M, Moretti A, et al. Endogenous androgens and carotid
14 intimal-medial thickness in women. *J Clin Endocrinol Metab*
15 1999;**84**(6):2008-12 doi: 10.1210/jcem.84.6.5824[published Online First:
16 Epub Date]].
17
18 49. Armeni E, Lambrinoudaki I, Ceausu I, et al. Maintaining postreproductive health:
19 A care pathway from the European Menopause and Andropause Society
20 (EMAS). *Maturitas* 2016;**89**:63-72 doi:
21 10.1016/j.maturitas.2016.04.013[published Online First: Epub Date]].
22
23 50. Abootalebi M, Kargar M, Jahanbin I, Sharifi AA, Sharafi Z. Knowledge and
24 Attitude about Andropause Among General Physicians in Shiraz, Iran 2014.
25 *Int J Community Based Nurs Midwifery* 2016;**4**(1):27-35
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **Figure legend**

41 **Fig 1 Prevalence of prediabetes and diabetes according to tertiles of**

42 **ApoB/ApoA-I ratio**

43
44
45
46 The numbers above the bars mean the prevalence of each outcome, respectively.
47
48

49 T1: tertile 1; T2: tertile 2; T3: tertile 3
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1

2

For peer review only

1

Table 1 Characteristics of participants according to glucose status and gender

	NGT			Prediabetes			Diabetes			P1	P2	P3
	Total	Men	Women	Total	Men	Women	Total	Men	Women			
Number	267	99	168	240	90	150	222	75	147	NS	NS	NS
Age	51.0	51.0	51.0	56.0	56.0	56.0	56.0	58.0	56.0	<0.001	<0.001	NS
(years)	(41.0,57.0)	(41.5,57.5)	(40.0,57.0)	(45.0,61.0)	(44.0,59.0)	(47.0,62.0)	(46.0,60.0)	(46.0, 61.5)	(46.0,59.5)			
SBP	114.0	114.0	110.0	121.0	116.0	121.0*	121.0	119.0	120.0	<0.001	<0.001	NS
(mmHg)	(113.0,116.0)	(102.0,127.0)	(102.0,120.5)	(119.0,123.0)	(110.0,131.0)	(114.0,132.0)	(119.0,123.0)	(113.0,129.5)	(110.0,130.5)			
DBP	74.0	72.0	74.0	77.0	78.0	78.0	80.0	79.0	79.0	<0.001	<0.001	0.005
(mmHg)	(73.0,75.0)	(68.0,79.0)	(69.0,80.0)	(76.0,78.0)	(72.0,83.0)	(74.0,82.0)	(78.0,81.0)	(73.5,82.0)	(75.5,85.5)			
BMI	23.03	23.11	23.06	23.92	24.12	23.64	25.09	27.67	23.37**	0.005	<0.001	<0.001

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

	(22.60,23.46)	(21.32,25.15)	(19.78,24.92)	(23.47,24.37)	(21.21,27.46)	(21.79,26.33)	(24.61,25.55)	(24.23,29.45)	(21.94,26.38)			
WHR	0.86	0.88	0.85*	0.89	0.89	0.89	0.90	0.91	0.90*	<0.001	<0.001	0.001
	(0.85,0.87)	(0.82,0.91)	(0.81,0.90)	(0.88,0.89)	(0.84,0.93)	(0.86,0.92)	(0.90,0.91)	(0.89,0.94)	(0.87,0.93)			
FPG	4.98	4.98	5.01	5.57	5.44	5.60	7.31	7.33	7.15**	<0.001	<0.001	<0.001
(mmol/L)	(4.87,5.09)	(4.65,5.25)	(4.75,5.35)	(5.46,5.69)	(4.92,5.97)	(5.04,6.11)	(7.19,7.43)	(7.16,8.06)	(5.73,7.87)			
2hPG	6.01	5.88	6.05	9.29	9.19	9.36	13.95	12.99	13.07	<0.001	<0.001	<0.001
(mmol/L)	(5.77,6.26)	(5.30,6.55)	(5.19,6.83)	(9.03,9.54)	(8.51,9.85)	(8.58,10.19)	(13.68,14.21)	(12.23,14.76)	(11.92,14.73)			
FINS	13.73	12.27	11.98	14.70	11.75	12.06	15.38	14.77	14.19	NS	0.014	NS
(µIU/L)	(12.85,14.61)	(9.51,16.90)	(8.76,20.11)	(13.78,15.61)	(10.59,17.71)	(10.74,18.71)	(14.42,16.33)	(10.80,20.03)	(9.82,18.29)			
2hINS	64.18	42.98	55.13	80.05	75.27	71.97	71.23	65.53	63.75*	0.001	NS	NS
(µIU/L)	(57.49,70.87)	(24.02,87.40)	(35.57,71.38)	(73.08,87.02)	(41.60,119.56)	(48.35,103.81)	(63.97,78.49)	(24.57,90.22)	(34.21,110.37)			
HbA1c	5.5	5.5	5.6	5.8	5.8	5.9*	6.9	6.9	6.7	<0.001	<0.001	<0.001
(%)	(5.4,5.6)	(5.2,5.7)	(5.3,5.8)	(5.7,5.9)	(5.5,6.0)	(5.6,6.1)	(6.8,7.0)	(6.6,7.3)	(6.0,7.4)			

HOMA-IR	3.07	2.63	2.67	3.72	2.93	3.28	5.04	4.82	4.18	0.001	<0.001	<0.001
	(2.81,3.33)	(2.01,3.86)	(1.95,4.60)	(3.46,3.99)	(2.27,4.18)	(2.58,4.58)	(4.76,5.32)	(3.46,7.29)	(3.15,5.85)			
HOMA-β	218.63	185.08	161.87	154.67	123.17	122.29	93.41	77.45	74.54	<0.001	<0.001	<0.001
	(203.73,233.53)	(136.51,246.24)	(124.18,257.26)	(139.14,170.19)	(94.47,185.50)	(87.07,186.75)	(77.24,109.58)	(58.17,88.08)	(55.07,112.40)			
TG	1.50	1.23	1.15	1.77	1.50	1.68	2.72	2.55	2.44	0.012	<0.001	<0.001
(mmol/L)	(1.36,1.65)	(0.77,1.70)	(0.77,1.77)	(1.62,1.92)	(1.06,1.99)	(1.09,2.24)	(2.56,2.88)	(1.73,4.14)	(1.69,3.50)			
TC	5.02	4.94	5.02*	5.13	5.15	5.27	5.64	5.47	5.90	NS	<0.001	<0.001
(mmol/L)	(4.92,5.12)	(4.67,5.20)	(4.67,5.40)	(5.03,5.23)	(4.31,5.78)	(4.66,5.55)	(5.53,5.75)	(5.13,6.18)	(4.93,6.29)			
HDL-C	1.48	1.43	1.45	1.34	1.30	1.29	1.23	1.12	1.28*	<0.001	<0.001	<0.001
(mmol/L)	(1.44,1.51)	(1.19,1.69)	(1.24,1.68)	(1.31,1.38)	(1.14,1.48)	(1.15,1.46)	(1.19,1.27)	(1.09,1.28)	(1.07,1.38)			
LDL-C	3.03	2.84	3.12	3.05	2.83	3.08	3.37	3.50	3.36	NS	<0.001	<0.001
(mmol/L)	(2.95,3.12)	(2.58,3.29)	(2.58,3.45)	(2.96,3.14)	(2.60,3.78)	(2.76,3.54)	(3.28,3.47)	(2.88,3.69)	(3.02,4.18)			
ApoA-I	1.48	1.43	1.45	1.39	1.40	1.34	1.33	1.36	1.31	<0.001	<0.001	0.005

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

(g/L)	(1.45,1.51)	(1.31,1.68)	(1.28,1.63)	(1.36,1.43)	(1.26,1.56)	(1.25,1.52)	(1.29,1.36)	(1.22,1.38)	(1.17,1.42)			
ApoB	0.84	0.80	0.84	0.91	0.90	0.97**	0.97	0.97	1.05**	<0.001	<0.001	0.001
(g/L)	(0.81,0.86)	(0.68,0.97)	(0.68,0.97)	(0.88,0.93)	(0.70,0.98)	(0.84,1.03)	(0.94,1.00)	(0.80,1.03)	(0.87,1.17)			
ApoB/Apo	0.60	0.55	0.56	0.67	0.66	0.74**	0.76	0.71	0.78**	<0.001	<0.001	<0.001
A-I ratio	(0.57,0.62)	(0.42,0.72)	(0.44,0.72)	(0.64,0.70)	(0.48,0.77)	(0.56,0.81)	(0.73,0.78)	(0.60,0.82)	(0.68,0.94)			

1 Data were expressed as medians (interquartile ranges 25-75%).

2 SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; WHR: waist to hip ratio; FPG: fasting plasma glucose;

3 2hPG: 2 hour postload plasma glucose; FINS: fasting serum insulin; 2hINS: 2 hour postload serum insulin; HbA1c: glycated hemoglobin A1c;

4 HOMA-IR: homeostatic model assessment of insulin resistance; HOMA- β : homeostatic model assessment of β -cell function; TG: triglyceride;

5 TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; ApoA-I: apolipoprotein A-I;

6 ApoB: apolipoprotein B.

7 P1: NGT versus prediabetic group, P2: NGT versus diabetic group, P3: prediabetic versus diabetic group

8 *P<0.05, **P<0.01 means the gender difference in each group

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

1 Comparisons among NGT, prediabetic and diabetic groups were performed after adjusting for age

For peer review only

1

Table 2 Partial correlation coefficients of ApoB/ApoA-I ratio with lipid profiles and glycometabolism-related traits

	NGT		Prediabetes		Diabetes	
	Men	Women	Men	Women	Men	Women
TG (mmol/L)	0.500 ^{***}	0.474 ^{***}	0.560 ^{***}	0.570 ^{***}	0.503 ^{***}	0.654 ^{***}
TC (mmol/L)	0.410 ^{***}	0.350 ^{***}	0.331 ^{**}	0.271 ^{**}	0.292 [*]	0.648 ^{***}
HDL (mmol/L)	-0.835 ^{***}	-0.727 ^{***}	-0.614 ^{***}	-0.563 ^{***}	-0.337 ^{**}	-0.721 ^{***}
LDL (mmol/L)	0.652 ^{***}	0.597 ^{***}	0.433 ^{***}	0.228 ^{**}	0.427 ^{***}	0.767 ^{***}
FPG (mmol/L)	0.340 ^{**}	0.261 ^{**}	0.432 ^{***}	0.296 ^{***}	0.675 ^{***}	0.471 ^{***}
2hPG (mmol/L)	0.550 ^{***}	0.277 ^{***}	0.198	0.287 ^{***}	0.300 [*]	0.162
FINS (μIU/mL)	0.281 ^{**}	0.195 [*]	0.370 ^{***}	0.122	0.581 ^{***}	0.463 ^{***}
2hINS (μIU/mL)	0.279 ^{**}	0.286 ^{***}	0.696 ^{***}	0.182 [*]	0.109	0.172 [*]
HbA1C (%)	0.253 [*]	0.254 ^{**}	0.274 [*]	0.213 [*]	0.265 [*]	0.278 ^{**}
HOMA-IR	0.326 ^{**}	0.225 ^{**}	0.427 ^{***}	0.175 [*]	0.677 ^{***}	0.584 ^{***}
HOMA-β	-0.007	-0.016	0.014	-0.084	0.208	-0.007

2 Data were analyzed after adjusting for age, SBP and DBP. Variables with skewed
3 distributions were log-transformed before statistical analysis.

4 * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$

5

6

7

Table 3. The risk of prediabetes and Type 2 diabetes according to tertiles of ApoB/ApoA-I ratio in men

		T1	T2	T3
		(0-0.5703)	(0.5704-0.7723)	(≥0.7724)
Prediabetes	n, cases/participants	32/102	34/90	24/72
	Model 1	1	1.602 (1.080, 2.122)*	1.427 (0.897, 1.997)
	Model 2	1	1.381 (0.868, 1.943)	1.160 (0.670, 1.758)
	Model 3	1	1.327 (0.813, 1.905)	1.113 (0.599, 1.769)
Type 2 Diabetes	n, cases/participants	18/102	31/90	26/72
	Model 1	1	2.461 (1.506, 3.510)**	2.394 (1.422, 3.485)**
	Model 2	1	2.035 (1.152, 3.126)*	1.901 (1.034, 3.022)*
	Model 3	1	1.643 (0.865, 2.723)	1.074 (0.481, 2.100)

1 Data are relative ratios (RR), 95% confidential intervals (CI).

2 Model 1: unadjusted

3 Model 2: adjusted for age, SBP, DBP

4 Model 3: adjusted for Model 2+ TC

5 * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$

6

7

8

9

10

11

12

13

14

Table 4. The risk of prediabetes and Type 2 diabetes according to tertiles of ApoB/ApoA-I ratio in women

		T1	T2	T3
		(0-0.5703)	(0.5704-0.7723)	(≥0.7724)
Prediabetes	n, cases/participants	40/141	48/153	62/171
	Model 1	1	1.568 (1.119, 2.044)**	2.221 (1.728, 2.647)***
	Model 2	1	1.317 (0.876, 1.826)	2.009 (1.472, 2.503)***
	Model 3	1	1.478 (0.898, 2.131)	2.186 (1.376, 2.842)**
Type 2 Diabetes	n, cases/participants	15/141	54/153	78/171
	Model 1	1	3.943 (2.540, 5.500)***	5.940 (4.353, 7.272)***
	Model 2	1	3.405 (2.078, 5.001)***	5.439 (3.767, 6.939)***
	Model 3	1	3.115 (1.598, 5.126)**	3.651 (1.685, 6.099)**


1 Data are relative ratios (RR), 95% confidential intervals (CI).

2 Model 1: unadjusted

3 Model 2: adjusted for age, SBP, DBP, BMI

4 Model 3: adjusted for Model 2+TC, TG, HDL-C, LDL-C

5 * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$



269x87mm (300 x 300 DPI)

peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	4
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4-5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4-5
Bias	9	Describe any efforts to address potential sources of bias	4
Study size	10	Explain how the study size was arrived at	4
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5-6
		(b) Describe any methods used to examine subgroups and interactions	5
		(c) Explain how missing data were addressed	5
		(d) If applicable, describe analytical methods taking account of sampling strategy	5
		(e) Describe any sensitivity analyses	6
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6
		(b) Give reasons for non-participation at each stage	6
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	6
		(b) Indicate number of participants with missing data for each variable of interest	6
Outcome data	15*	Report numbers of outcome events or summary measures	6
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	6-7
		(b) Report category boundaries when continuous variables were categorized	7
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	7
Discussion			7
Key results	18	Summarise key results with reference to study objectives	7-8
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10
Generalisability	21	Discuss the generalisability (external validity) of the study results	11
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	11

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Associations of Apolipoprotein B to A-I ratio with pre-diabetes and diabetes risks: a cross-sectional study in Chinese adults

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-014038.R2
Article Type:	Research
Date Submitted by the Author:	06-Dec-2016
Complete List of Authors:	Zheng, Shuang; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Han, Tingting; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Xu, Hua; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Zhou, Huan; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Ren, Xingxing; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Wu, Peihong; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Zheng, Jun; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Wang, Lihua; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Zhang, Ming; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Jiang, Yihong; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Chen, Yawen; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Qiu, Huiying; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Liu, Wei; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Department of Endocrinology Hu, Yaomin; Shanghai Jiaotong University, Department of Endocrinology
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Diabetes and endocrinology, Diagnostics, Evidence based practice, Public health
Keywords:	apolipoprotein B, apolipoprotein A-I, type 2 diabetes, prediabetes, dyslipidemia

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2016-014038 on 20 January 2017. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.

1
2
3
4 **Title Page**

5
6 **Associations of Apolipoprotein B to A-I ratio with pre-diabetes and diabetes**
7
8
9 **risks: a cross-sectional study in Chinese adults**

10
11 Shuang Zheng^{1*}, Tingting Han^{1*}, Hua Xu^{1*}, Huan Zhou¹, Xingxing Ren¹,
12
13 Peihong Wu¹, Jun Zheng¹, Lihua Wang¹, Ming Zhang¹, Yihong Jiang¹, Yawen
14
15 Chen¹, Huiying Qiu¹, Wei Liu^{1#}, Yaomin Hu^{1#}
16
17
18
19

20
21
22 1 Department of Endocrinology, Renji Hospital, School of Medicine, Shanghai
23
24 Jiaotong University, Shanghai 200127, China
25
26

27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

11 * Contributed equally to this work

12 # Corresponding author

13 Yaomin Hu: amin1031@sina.cn

14 Wei Liu: sue_liuwei@163.com

15 Address: Department of Endocrinology, Renji Hospital, School of Medicine,
16 Shanghai Jiaotong University, No.1630 Dongfang Road, Shanghai 200127,
17 China.

1
2
3
4 **1 Abstract**

5
6 **2 Objectives** Apolipoprotein (Apo)B/ApoA-I ratio is a useful predictor of cardiovascular
7
8 risk. However, the association between the ApoB/ApoA-I ratio and the risk of type 2
9
10 diabetes mellitus (T2DM) is still obscure. The aims of the study were to investigate the
11
12 associations between the ApoB/ApoA-I ratio and the risk of T2DM and pre-diabetes in
13
14 a Chinese population and also assess the role of gender in these associations.
15
16
17
18

19 **7 Participants and Methods** A stratified random sampling design was used in this
20
21 cross-sectional study which included 264 men and 465 women with normal glucose
22
23 tolerance (NGT), pre-diabetes or T2DM. Serum Apo B, Apo A-I and other lipid and
24
25 glycaemic traits were measured. Pearson's partial correlation and multivariable logistic
26
27 analysis were used to evaluate the associations between ApoB/ApoA-I ratio and the
28
29 risk of T2DM and pre-diabetes.
30
31
32
33

34 **13 Results** The ApoB/ApoA-I ratios were significantly increased across the spectrum of
35
36 NGT, pre-diabetes and T2DM. Women showed higher levels of ApoB/ApoA-I ratio
37
38 and ApoB than men in pre-diabetic and T2DM groups, but not in NGT group.
39
40 ApoB/ApoA-I ratio was closely related with TG, TC, HDL-C, LDL-C and other
41
42 glycaemic traits. Moreover, in women, the risk of diabetes and pre-diabetes in the top
43
44 and middle tertiles of ApoB/ApoA-I ratio were 3.65- (95%CI: 1.69-6.10) and
45
46 2.19-fold (95%CI: 1.38-2.84) higher than in the bottom tertile respectively, after
47
48 adjusting for potential confounding factors. However, the associations disappeared in
49
50 men after adjusting for other factors.
51
52
53
54
55
56
57
58
59
60

1
2
3
4 1 **Conclusions** The ApoB/ApoA-I ratio showed positive associations with the risk of
5
6 2 diabetes and pre-diabetes in Chinese women.
7
8
9 3

10
11 4 **Strengths and limitations of this study**
12

- 13
14 5 ● This is an in-depth investigation of the associations between ApoB/ApoA-I ratio
15
16 6 and diabetes or pre-diabetes in Chinese population.
17
18 7 ● Stratified random sampling ensured equal chance for participant enrolment and
19
20 8 the validity of results.
21
22 9 ● Data collection and analysis were supported by trained survey team, which
23
24 10 included researchers with differing areas of expertise and backgrounds.
25
26 11 ● The cross-sectional design does not confirm the causality between ApoB/ApoA-I
27
28 12 ratio and diabetes risk.
29
30 13 ● Potential bias might exist in a single-centre design.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

15 **Keywords:** apolipoprotein B; apolipoprotein A-I; type 2 diabetes; pre-diabetes;
16 dyslipidemia
17
18
19
20
21
22

1 Introduction

2 Atherogenic dyslipidemia is a characteristic lipoprotein abnormality that includes
3 high levels of triglyceride (TG)-rich lipoproteins (mainly very low-density lipoprotein
4 [VLDL]), low levels of high-density lipoproteins (HDL) and an elevated proportion of
5 small dense low-density lipoprotein (sd-LDL) particles [1]. To date, evaluation of the
6 clinical relevance of atherogenic dyslipidemia has focused on its role as an effective
7 predictor of cardiovascular disease (CVD) compared to other lipid parameters.
8 Apolipoproteins are important structural and functional proteins in lipoprotein particles.
9 Given that circulating levels of apolipoproteins indicate the number of lipoprotein
10 particles, the level of Apo-B reflects the total number of potentially atherogenic
11 particles, including VLDL, intermediate density lipoproteins, large buoyant LDL, and
12 sd-LDL, and the level of ApoA-I represents the number of HDL particles [2]. Thus, the
13 ratio of apolipoproteins B to A-I (ApoB/ApoA-I) would theoretically be an ideal
14 indicator of atherogenic lipid disturbances and cardiovascular risk [3 4].

15 It is well established that atherogenic dyslipidemia is associated with T2DM and
16 high risk of CVD in T2DM patients [5 6]. Moreover, the mortality rate of CVD in
17 diabetic patients varies with gender [7]. Previous studies have demonstrated that
18 ApoB/ApoA-I ratio may be a strong marker of metabolic syndrome and insulin
19 resistance in certain population [8-10], but the associations of it with T2DM and
20 pre-diabetes as well as its gender effects in Chinese population are still poorly clarified.
21 Additionally, the correlations between ApoB/ApoA-I ratio and other lipid or glycaemic

1 traits, such as TG, TC, glucose, insulin sensitivity and secretion, need further
2 investigation.

3 Therefore, in this observational study, we aimed to evaluate the associations
4 between the level of ApoB/ApoA-I ratio and the risk of T2DM, pre-diabetes in both
5 Chinese men and women and also investigate the correlations between the ratio and
6 other lipid and glycaemic traits.

7 8 **Subjects and Methods**

9 **Subjects**

10 Stratified random sampling was performed to select participants from the database
11 of Renji Hospital from January 2010 to December 2014. A total of 1538 subjects aged
12 18 to 80 years were included. All of them had visited the Department of Endocrinology,
13 Renji Hospital, School of Medicine, Shanghai Jiaotong University for a health
14 check-up.

15 The exclusion criteria were regular diabetic and/or lipid-lowering medication use, a
16 history of cardiovascular disease, cerebrovascular disease, chronic renal or hepatic
17 failure, cancer, pregnant, hyperthyroidism and hypothyroidism. Subjects with
18 incomplete data were also excluded.

19 Finally, 729 subjects (264 men and 465 women) were involved in this study. The
20 study was carried out in accordance with the declaration of Helsinki and the study
21 protocol was approved by the Ethical Committee of Renji Hospital, School of Medicine,
22 Shanghai Jiaotong University. Written informed consents were obtained from all

1 subjects included in the study.

2

3 **Anthropometry measurements**

4 Height, body weight, waist circumference (WC), hip circumference and blood
5 pressure (BP) were measured by trained survey personnel. Height was measured once
6 with a portable height scale to the nearest 0.1 cm. Weight was measured using a
7 platform digital scale to the nearest 0.1kg. Both height and weight measurements were
8 taken in light clothing without shoes. Waist circumference was recorded as the
9 circumference midpoint between the iliac crest and the lowest rib. Hip circumference
10 was recorded as the largest gluteal circumference. Circumference measurements were
11 taken twice by a single observer and the mean value was reported. Blood pressure was
12 measured twice in each subject on the right arm after a five-minute rest in a sitting
13 position, and the mean of two measurements was used.

14

15 **Laboratory analysis**

16 All subjects underwent the standard 75g glucose oral glucose tolerance test (OGTT)
17 after an 8-hour overnight fast. Serum ApoB (predominantly ApoB-100) and ApoA-I
18 concentrations were determined by immunoturbidimetric methods using automatic
19 immunoassay analyzer (Roche E-170, Roche, Basel, Switzerland). Glucose and other
20 lipid levels were measured using fully automatic biochemistry analyzer (Hitachi 7600–
21 110 and Hitachi 7020, respectively, Hitachi Co. Tokyo, Japan); Insulin concentration
22 was determined by immunoradiometric assay kit (Dainabot, Tokyo, Japan);

1 Hemoglobin A1c (HbA1c) level was measured by high-performance liquid
2 chromatography.

3

4 **Definition of T2DM and pre-diabetes**

5 According to the 2006 World Health Organization criteria [11], diabetes was
6 defined as fasting plasma glucose (FPG) ≥ 7.0 mmol/L and/or 2-h post-load plasma
7 glucose (2hPG) ≥ 11.1 mmol/L; pre-diabetes was defined as FPG between 6.1mmol/L
8 and 7.0mmol/L and/or 2hPG between 7.8mmol/L and 11.1mmol/L. For diabetes, the
9 diagnosis was predominately based on the results of the 75g OGTT. In addition, the
10 level of HbA1c $> 6.5\%$ was also considered as a supplementary criterion. If a subject
11 met both criteria, then the diagnosis of diabetes was certain. However, if a subject met
12 the criteria of OGTT but the level of HbA1c was $< 6.5\%$, then the OGTT would be
13 repeated within one month. Two abnormal measurements of OGTT confirmed the
14 diagnosis of diabetes. If a subject didn't meet the criteria of OGTT at the first time, then
15 he or she would be excluded. For pre-diabetes, the diagnosis would be ensured with
16 repeated OGTT in one month. Anyone who didn't meet the criteria of OGTT at the
17 second time would be excluded. Besides, subjects who declined to take the second
18 examination were also excluded.

19

20 **Calculation**

21 Body mass index (BMI) was defined as the body weight (kg) divided by the square

1 of body height (m²). Waist to hip ratio (WHR) was calculated as waist circumference
2 (cm) divided by hip circumference (cm). Indices of insulin resistance and insulin
3 secretion were calculated from the OGTT data: homeostasis model assessment for
4 insulin resistance (HOMA-IR) = fasting insulin (μU/ml) × fasting glucose (mmol/L)
5 /22.5; homeostasis model assessment for β cell function index (HOMA-β) = 20×fasting
6 insulin in μU/ml / (fasting glucose in mmol/L -3.5).

7 8 **Statistical analysis**

9 All statistical analyses were performed using SPSS Version 17.0 (SPSS Inc.,
10 Chicago, IL, USA). The available-case analysis (pairwise deletion) was applied to
11 handle missing data. Continuous data were expressed as median (Interquartile range
12 25-75%) due to the skewed distribution and compared by Kruskal-Wallis H test or
13 Mann–Whitney U test. Adjusted means were calculated and compared with general
14 linear models. Categorical variables were shown as percentages and compared with
15 Chi-square test. A Pearson’s partial correlation analysis was carried out to identify the
16 correlativity between ApoB/ApoA-I ratio and other variables after adjusting for several
17 covariates. Data with skewed distribution were log-transformed before analysis. A
18 multivariable logistic regression model was conducted to test the associations between
19 ApoB/ApoA-I ratio and the risk of pre-diabetes and diabetes after controlling for
20 potential confounding factors. The relative ratios (RR) and 95% confidence intervals
21 (CIs) of tertiles 2 to 3 were calculated and compared by using tertile 1 as reference. RR
22 was calculated based on the formula: $RR=OR/(1-P_0+P_0*OR)$, where OR was odds

1 ratio and P0 was the disease incidence in non-exposed group. Statistical significance
2 was considered at $p < 0.05$.

3

4 **Results**

5 **Clinical and laboratory characteristics**

6 After excluding ineligible subjects on the basis of exclusion criteria and those
7 unable to finish the study, 729 subjects were finally included in this study. Among these
8 eligible participants, 36.2% were men and 63.8% were women, with a mean age of 51.2
9 years. 30.5% of subjects (28.4% men and 31.6% women) were diagnosed as T2DM,
10 32.9% (34.1% men and 32.3% women) as pre-diabetes, and 36.6% (37.5% men and
11 36.1% women) as having normal glucose tolerance (NGT).

12 The anthropometric and metabolic characteristics of the participants are presented in
13 Table 1. Subjects with T2DM had much higher ApoB/ApoA-I ratios than those with
14 pre-diabetes and NGT, accompanied by worse glucose and lipid profiles. Moreover,
15 T2DM subjects showed higher levels of BP, BMI and WHR. Subjects with pre-diabetes
16 had higher ApoB/ApoA-I ratios than those with NGT. The levels of BP, BMI and WHR
17 in the pre-diabetic group were also higher than those with NGT.

18 When men and women were analysed separately, the ApoB/ApoA-I ratio in women
19 was higher than in men both in T2DM and pre-diabetic groups. However, the gender
20 difference in NGT group was not significant. Additionally, the levels of ApoB in
21 women were also higher than in men in both T2DM and pre-diabetic groups. But other
22 lipid indices including TG, TC and LDL-C showed little difference between men and

1
2
3
4 1 women.
5
6
7 2
8

9 **3 Correlations between ApoB/ApoA-I ratio and other variables**

10
11 4 After adjusting for age, systolic and diastolic BP, Pearson's partial correlation
12
13 5 analysis showed that ApoB/ApoA-I ratio was positively correlated with TG, TC,
14
15 6 LDL-C and negatively correlated with HDL-C, in all 3 groups (Table 2). Gender
16
17 7 difference was insignificant. In addition, ApoB/ApoA-I ratio was strongly associated
18
19 8 with FPG, HbA1C and HOMA-IR both in men and women. However, the correlations
20
21 9 between ApoB/ApoA-I ratio and HOMA- β , insulin levels were not significant.
22
23
24
25
26
27
28

29 **11 Risk of pre-diabetes and diabetes according to ApoB/ApoA-I ratio**

30
31
32 12 The ApoB/ApoA-I ratios were further divided into tertiles and the first tertile was
33
34 13 regarded as the reference group. In men, the risk of pre-diabetes in tertile 2 was
35
36 14 1.60-fold higher than in the first tertile (RR=1.602, 95%CI:1.080-2.122 $p<0.05$).
37
38 15 However, this association disappeared after adjusting for age, SBP, DBP and TC. In
39
40 16 parallel with pre-diabetes, the association of ApoB/ApoA-I ratio with diabetes also
41
42 17 disappeared after adjusting for the aforementioned confounding factors in men (Table
43
44 18 3).
45
46
47
48

49
50 19 Nevertheless, the associations between ApoB/ApoA-I ratio and pre-diabetes or
51
52 20 diabetes risk in women were more obvious than in men (Table 4). In women, the risk of
53
54 21 pre-diabetes was increased across the tertile of ApoB/ApoA-I ratio (T2: RR=1.568,
55
56 22 95%CI: 1.119-2.044, $p<0.01$; T3: RR=2.221, 95%CI: 1.728-2.647, $p<0.001$). After
57
58
59
60

1
2
3
4 1 adjusting for age, SBP, DBP, BMI and other lipid levels, the association between
5
6 2 ApoB/ApoA-I ratio and pre-diabetes was attenuated but still significant in T3 group
7
8
9 3 (RR=2.186, 95%CI: 1.376-2.842, $p<0.01$). Moreover, the crude RRs and 95%CI of
10
11 4 diabetes in tertile 2 to 3 were 3.943 (95%CI: 2.540-5.500, $p<0.001$) and 5.940
12
13 5 (95%CI: 4.353-7.272, $p<0.001$), respectively. After further adjusting for confounding
14
15 6 factors, the risk of diabetes in the top tertile of ApoB/ApoA-I ratio was still 3.65-fold
16
17 7 higher than in the bottom tertile (RR=3.651, 95%CI: 1.685-6.099, $p<0.01$).
18
19
20
21
22
23

24 9 **Prevalence of pre-diabetes and diabetes according to tertile of ApoB/ApoA-I ratio**

25
26
27 10 As shown in **Fig 1**, the prevalence of pre-diabetes and T2DM in women were
28
29 11 increased in sequence from the bottom to the top tertiles of ApoB/ApoA-I ratio (for
30
31 12 pre-diabetes: T1:16.5%, T2:19.8%, T3:25.5%, $p=0.014$; for diabetes, T1:6.2%,
32
33 13 T2:22.2%, T3:32.1%, $p<0.001$). However, the prevalence of pre-diabetes and diabetes
34
35 14 in men were higher in T2 than in T1 and T3 (for pre-diabetes: T1:13.2%, T2:14.0%,
36
37 15 T3:9.9%, $p>0.05$; for diabetes, T1:7.4%, T2:12.8%, T3:10.7%, $p>0.05$).
38
39
40
41
42
43

44 17 **Discussion**

45
46
47 18 In the current cross-sectional study, we observed strong positive associations
48
49 19 between the ApoB/ApoA-I ratio and the risk of pre-diabetes and diabetes in women,
50
51 20 independent of traditional metabolic risk factors. However, the associations in men
52
53 21 were insignificant after adjusting for potential confounding factors. ApoB/ApoA-I
54
55 22 ratio was closely correlated with other lipid parameters and insulin resistance both in
56
57
58
59
60

1 men and women.

2 It is well known that ApoB/ApoA-I ratio is a better predictor of cardiovascular
3 risk than other conventional lipid indices [12]. However, only a few studies have shown
4 the associations between apolipoprotein levels and the risk of diabetes. Hwang et al.
5 [13] indicated that ApoB/ApoA-I ratio is an effective predictor of T2DM in the Korean
6 population. The ApoB/LDL-C ratio has been associated with T2DM in a
7 population-based study of Turkish adults [14] and ApoB in the Aboriginal Canadian
8 population [15]. Our results consistently suggested that ApoB/ApoA-I ratio was
9 associated with diabetes and pre-diabetes in Chinese women. Furthermore,
10 ApoB/ApoA-I ratio was closely correlated with TG, TC, HDL-C, LDL-C, FPG,
11 HbA1C and HOMA-IR, which is in accordance with previous studies [10 16].

12 Apolipoproteins regulate the synthesis and metabolism of lipoprotein particles and
13 stabilize their structures. Hence, it is not unexpected that ApoB/ApoA-I ratio was
14 closely related with TG, TC, HDL-C and LDL-C. Apolipoprotein B and A-I are the
15 major protein moieties of LDL and HDL, respectively. The level of ApoB reflects the
16 number of potentially atherogenic particles [17]. Meanwhile, ApoA-I plays an
17 important role in removing excess cholesterol from tissues and incorporating it into
18 HDL for reverse transport to the liver, forming the basis for atheroprotective events [18
19 19]. Thus, ApoB/ApoA-I ratio reflects the balance of atherogenic and atheroprotective
20 particles, so the higher the level, the higher the tendency of cholesterol deposition, and
21 consequently the higher the risk of CVD [20].

1 Development of hyperglycemia is closely associated with lipid disturbances [21
2 22]. In diabetic dyslipidemia, ApoB-containing lipoprotein particles undergo
3 compositional changes, including the increased formation of sd-LDL and large VLDL
4 (VLDL-1) particles [23-25]. These features were present in up to 50% of T2DM
5 patients [26 27] and even in pre-diabetic patients with insulin resistance but normal
6 glucose tolerance [28]. This relationship has been demonstrated by several prospective
7 studies, which indicated that increased levels of TG, sd-LDL, VLDL-1 and small HDL
8 particles are closely associated with incident diabetes, whereas elevated levels of large
9 HDL particles and Apo A-I are negatively associated with diabetes [29-31]. In our
10 study, we found the levels of ApoB were significantly increased in subjects with
11 diabetes and pre-diabetes while the levels of ApoA-I showed the opposite trend across
12 the spectrum of NGT, pre-diabetes and diabetes. As a consequence, the ratio of
13 ApoB/ApoA-I was positively associated with pre-diabetes and diabetes. Moreover, this
14 ratio was significantly correlated with insulin resistance. Previous studies have
15 demonstrated that the ApoB/ApoA-I ratio is an independent predictor of insulin
16 resistance in US non-diabetic subjects [32] and Chinese obesity subjects [33]. A
17 possible explanation for the positive association between the ApoB/ApoA-I ratio and
18 insulin resistance could be that both ApoB and insulin resistance are linked to an
19 inflammatory state [34]. However, detailed mechanisms interpreting this association
20 need further exploration.

1
2
3
4 1 The mechanisms leading to the accumulation of triglyceride-rich lipoproteins
5
6 2 (TRLs) in patients with T2DM have not been fully elucidated. Hogue et al. [35]
7
8
9 3 demonstrated that the elevated apoB48-containing TRLs of intestinal origin and
10
11 4 apoB100-containing TRLs of hepatic origin in diabetic subjects are due to the increased
12
13
14 5 production rates and decreased catabolism of these particles. Furthermore, Duez et al.
15
16 6 [36] showed that intestinal secretion of apoB48-containing TRLs is increased in
17
18
19 7 insulin-resistant subjects with hyperinsulinemia.
20

21
22 8 The effects of gender on lipid and apolipoprotein metabolism have been reported in
23
24 9 several studies. Anahostis et al. [37] conducted a cross-sectional study in
25
26
27 10 premenopausal and postmenopausal Caucasian women, and men and they showed that
28
29
30 11 ApoB concentrations were higher in men than in women. In women, the levels rose
31
32
33 12 with age. Apo A-I concentrations are highest in postmenopausal women and lowest in
34
35
36 13 men. Li et al. [38] observed that postmenopausal status resulted in higher levels of all
37
38 14 ApoB-containing lipoproteins. Hence, the risk of CVD was increased in women after
39
40
41 15 menopause. The mechanisms of the gender effects on lipoprotein and apolipoprotein
42
43 16 metabolism are not clear, but may be related to sex hormone changes. Some authors
44
45
46 17 have reported that serum estrone or estradiol levels are positively correlated with
47
48
49 18 HDL-C and TG and inversely associated with TC and LDL-C [39 40]. Androgen
50
51
52 19 excess in premenopausal women, as is the case of polycystic ovary syndrome (PCOS),
53
54
55 20 has been associated with increased TG and sd-LDL particles, as well as reduced
56
57
58 21 HDL-C [41]. In addition, hyperandrogenemic women demonstrate increased insulin
59
60

1 resistance and incidence of CVD [42]. However, some other studies have reported
2 conflicting results about the effects of estrone and androgen [43 44].

3 In our study, it is noticeable that the gender difference was not significant in NGT
4 groups. In pre-diabetic and diabetic groups, the levels of ApoB were increased in
5 women, as were the ApoB/ApoA-I ratios. The results might be interpreted to indicate
6 that age, gender, hormone levels, glucose and lipid levels exist in a complicated relative
7 network and the corroborative effects of hormone and glucose status may accentuate
8 the gender difference. We found the association between ApoB/ApoA-I ratio and the
9 risk of diabetes was still significant in women after adjusting for conventional factors.
10 Unfortunately, women were not further divided into premenopausal and
11 postmenopausal groups due to the lack of information on menopausal status. However,
12 from the median age of women in pre-diabetic and diabetic groups (56.0 years old), we
13 may make an inference that a great number of these women were in the postmenopausal
14 status, which may, to some extent, explain the higher levels of ApoB in women groups
15 and also the higher risk of pre-diabetes and diabetes in women. In men, hormonal
16 changes in andropause are not as recognizable as in female menopause [45 46] but they
17 could also have an influence on our data. The risk of diabetes in men could also be
18 derived from various factors, such as work stress, smoking and drinking and the lack of
19 physical exercise. The number of male participants included in this study was relatively
20 small. These factors may be responsible for the lack of significant association between
21 ApoB/ApoA-I ratio and diabetes risk in men.

1
2
3
4 1 There were some limitations in our study. First, it was performed using a
5
6 2 cross-sectional design and did not control for potential biases from diet, physical
7
8
9 3 activity, smoking and drinking history. Second, women were not further divided
10
11 4 according to menopausal status. Therefore, a prospective and well-controlled study
12
13 5 would be needed to elucidate the associations of apoB/ApoA-I ratio with diabetes and
14
15 6 pre-diabetes risk.
16
17
18
19

20 7 In conclusion, our findings indicate positive associations between ApoB/ApoA-I
21
22 8 ratio and the risk of pre-diabetes and diabetes in Chinese women, independent of
23
24 9 traditional metabolic risk factors. However, the associations in men were insignificant
25
26 10 after adjusting for potential comfounding factors. Collectively, the results of this study
27
28 11 provide valuable evidence for a better understanding of ApoB/ApoA-I ratio in
29
30 12 detecting pre-diabetes and diabetes risk in Chinese population, especially in women.
31
32 13 Therefore, we propose the possibility of applying this ratio for risk assessment in
33
34 14 Chinese women in epidemiologic investigation or routine clinical practice.
35
36
37
38
39
40
41
42
43
44

45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

16 **Competing interests**

17 We declare that we have no conflict of interest.

18 **Financial support**

1 This study was supported by the National Natural Science Foundation of China (No.
2 81270946, 81170758, 30670988) and the Foundation from Renji Hospital, School of
3 Medicine, Shanghai Jiaotong University (RJZZ14-003).

4 **Author contributions**

5 SZ, TH and HX attended the statistical analysis, data interpretation, manuscript writing
6 and revision. HZ, XR, PW, YZ and LW contributed to data interpretation. ME, YJ, YC
7 and HQ contributed to data collection. WL contributed to data collection and revision
8 of the paper. YH contributed to acquisition of funding, study design, and revision of the
9 paper. All authors revised and approved the final manuscript.

10 **Acknowledgements**

11 The authors thank the staff of the Endocrinology and Metabolism Laboratory and the
12 nursing staff for their dedicated assistance in patient sample collection. We also greatly
13 appreciate Dr. Teik Chye Ooi, from Division of Endocrinology and Metabolism, the
14 Ottawa Hospital, University of Ottawa, Canada for his professional English language
15 editing of this article.

16
17 **Data sharing statement** Additional research data will be made available to the
18 scientific community with as few restrictions as possible.

19 20 **References**

21 1. Christen A, Efstathiadou Z, Laspa E, Johnston DG, Godsland IF. Rate of change
22 and instability in body mass index, insulin resistance, and lipid metabolism as

- 1
2
3 1 predictors of atherosclerotic vascular disease. *J Clin Endocrinol Metab*
4 2007;**92**(10):3780-7 doi: 10.1210/jc.2006-2267[published Online First: Epub
5 2 Date]].
6 3
7 4 2. Alfadda AA, Al-Daghri NM, Malabu UH. Apolipoprotein B/apolipoprotein A-I
8 ratio in relation to various definitions of metabolic syndrome among Saudi
9 patients with type 2 diabetes mellitus. *Saudi Med J* 2008;**29**(6):821-5
10 5
11 6
12 7 3. Sniderman AD. Non-HDL cholesterol versus apolipoprotein B in diabetic
13 dyslipoproteinemia: alternatives and surrogates versus the real thing. *Diabetes*
14 *Care* 2003;**26**(7):2207-8
15 8
16 9
17 10 4. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of
18 coronary heart disease and targets for lipid-modifying therapy. *J Intern Med*
19 2004;**255**(2):188-205
20 11
21 12
22 13 5. Adiels M, Olofsson SO, Taskinen MR, Boren J. Diabetic dyslipidaemia. *Curr Opin*
23 *Lipidol* 2006;**17**(3):238-46 doi:
24 14
25 10.1097/01.mol.0000226115.97436.c0[published Online First: Epub Date]].
26 15
27 16 6. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice.
28 *Diabetologia* 2003;**46**(6):733-49 doi: 10.1007/s00125-003-1111-y[published
29 17
30 Online First: Epub Date]].
31 18
32 19 7. Legato MJ, Gelzer A, Golland R, et al. Gender-specific care of the patient with
33 diabetes: review and recommendations. *Gend Med* 2006;**3**(2):131-58
34 20
35 21 8. Solymoss BC, Bourassa MG, Campeau L, et al. Effect of increasing metabolic
36 syndrome score on atherosclerotic risk profile and coronary artery disease
37 angiographic severity. *Am J Cardiol* 2004;**93**(2):159-64
38 22
39 23
40 24 9. Lind L, Vessby B, Sundstrom J. The apolipoprotein B/AI ratio and the metabolic
41 syndrome independently predict risk for myocardial infarction in middle-aged
42 men. *Arterioscler Thromb Vasc Biol* 2006;**26**(2):406-10 doi:
43 25
44 10.1161/01.ATV.0000197827.12431.d0[published Online First: Epub Date]].
45 26
46 27 10. Sierra-Johnson J, Somers VK, Kuniyoshi FH, et al. Comparison of
47 apolipoprotein-B/apolipoprotein-AI in subjects with versus without the
48 metabolic syndrome. *Am J Cardiol* 2006;**98**(10):1369-73 doi:
49 28
50 10.1016/j.amjcard.2006.06.029[published Online First: Epub Date]].
51 29
52 30
53 31 11. Health Organization and International Diabetes Foundation, Definition and
54 diagnosis of diabetes mellitus and intermediate hyperglycemia: Report of a
55 32
56 33

- 1 WHO/IDF consultation. 2006, Geneva: World Health organization.
- 2 12. Montali A, Truglio G, Martino F, et al. Atherogenic dyslipidemia in children:
3 evaluation of clinical, biochemical and genetic aspects. PLoS One
4 2015;**10**(4):e0120099 doi: 10.1371/journal.pone.0120099[published Online
5 First: Epub Date]].
- 6 13. Hwang YC, Ahn HY, Kim WJ, Park CY, Park SW. Increased apoB/A-I ratio
7 independently associated with Type 2 diabetes mellitus: cross-sectional study
8 in a Korean population. Diabet Med 2012;**29**(9):1165-70 doi:
9 10.1111/j.1464-5491.2012.03622.x[published Online First: Epub Date]].
- 10 14. Onat A, Can G, Cicek G, Ayhan E, Dogan Y. Predictive value of serum
11 apolipoprotein B/LDL-cholesterol ratio in cardiometabolic risk:
12 population-based cohort study. Clin Biochem 2010;**43**(18):1381-6 doi:
13 10.1016/j.clinbiochem.2010.08.027[published Online First: Epub Date]].
- 14 15. Ley SH, Harris SB, Connelly PW, et al. Association of apolipoprotein B with
15 incident type 2 diabetes in an aboriginal Canadian population. Clin Chem
16 2010;**56**(4):666-70 doi: 10.1373/clinchem.2009.136994[published Online First:
17 Epub Date]].
- 18 16. Wallenfeldt K, Bokemark L, Wikstrand J, Hulthe J, Fagerberg B. Apolipoprotein
19 B/apolipoprotein A-I in relation to the metabolic syndrome and change in
20 carotid artery intima-media thickness during 3 years in middle-aged men.
21 Stroke 2004;**35**(10):2248-52 doi:
22 10.1161/01.STR.0000140629.65145.3c[published Online First: Epub Date]].
- 23 17. Krychtiuk KA, Kastl SP, Pfaffenberger S, et al. Association of small dense LDL
24 serum levels and circulating monocyte subsets in stable coronary artery
25 disease. PLoS One 2015;**10**(4):e0123367 doi:
26 10.1371/journal.pone.0123367[published Online First: Epub Date]].
- 27 18. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J
28 Lipid Res 1995;**36**(2):211-28
- 29 19. Rosu SA, Rimoldi OJ, Prieto ED, et al. Amyloidogenic propensity of a natural
30 variant of human apolipoprotein A-I: stability and interaction with ligands.
31 PLoS One 2015;**10**(5):e0124946 doi:
32 10.1371/journal.pone.0124946[published Online First: Epub Date]].
- 33 20. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for

- 1
2
3 1 cardiovascular disease and a target for lipid-lowering therapy--a review of the
4 evidence. *J Intern Med* 2006;**259**(5):493-519 doi:
5 10.1111/j.1365-2796.2006.01643.x[published Online First: Epub Date]].
6
7
8 21. Zheng S, Zhou H, Han T, et al. Clinical characteristics and beta cell function in
9 Chinese patients with newly diagnosed type 2 diabetes mellitus with different
10 levels of serum triglyceride. *BMC Endocr Disord* 2015;**15**:21 doi:
11 10.1186/s12902-015-0018-1[published Online First: Epub Date]].
12
13 22. Ren X, Chen ZA, Zheng S, et al. Association between Triglyceride to HDL-C
14 Ratio (TG/HDL-C) and Insulin Resistance in Chinese Patients with Newly
15 Diagnosed Type 2 Diabetes Mellitus. *PLoS One* 2016;**11**(4):e0154345 doi:
16 10.1371/journal.pone.0154345[published Online First: Epub Date]].
17
18 23. Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM. Lipoprotein
19 particle size and concentration by nuclear magnetic resonance and incident
20 type 2 diabetes in women. *Diabetes* 2010;**59**(5):1153-60 doi:
21 10.2337/db09-1114[published Online First: Epub Date]].
22
23 24. Austin MA, Mykkanen L, Kuusisto J, et al. Prospective study of small LDLs as a
24 risk factor for non-insulin dependent diabetes mellitus in elderly men and
25 women. *Circulation* 1995;**92**(7):1770-8
26
27 25. Fagot-Campagna A, Knowler WC, Narayan KM, Hanson RL, Saaddine J, Howard
28 BV. HDL cholesterol subfractions and risk of developing type 2 diabetes
29 among Pima Indians. *Diabetes Care* 1999;**22**(2):271-4
30
31 26. Abate N, Vega GL, Garg A, Grundy SM. Abnormal cholesterol distribution among
32 lipoprotein fractions in normolipidemic patients with mild NIDDM.
33 *Atherosclerosis* 1995;**118**(1):111-22
34
35 27. Caixas A, Ordonez-Llanos J, de Leiva A, Payes A, Homs R, Perez A.
36 Optimization of glycemic control by insulin therapy decreases the proportion
37 of small dense LDL particles in diabetic patients. *Diabetes*
38 1997;**46**(7):1207-13
39
40 28. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin-resistant
41 prediabetic subjects have more atherogenic risk factors than insulin-sensitive
42 prediabetic subjects: implications for preventing coronary heart disease during
43 the prediabetic state. *Circulation* 2000;**101**(9):975-80
44
45 29. Mackey RH, Mora S, Bertoni AG, et al. Lipoprotein particles and incident type 2
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1 diabetes in the multi-ethnic study of atherosclerosis. *Diabetes Care*
4 2015;**38**(4):628-36 doi: 10.2337/dc14-0645[published Online First: Epub
5 Date]].
6
7 3
8
9 4 30. Abbasi A, Corpeleijn E, Gansevoort RT, et al. Role of HDL cholesterol and
10 estimates of HDL particle composition in future development of type 2
11 diabetes in the general population: the PREVEND study. *J Clin Endocrinol*
12 *Metab* 2013;**98**(8):E1352-9 doi: 10.1210/jc.2013-1680[published Online First:
13 Epub Date]].
14 8
15 9 31. Fagot-Campagna A, Narayan KM, Hanson RL, et al. Plasma lipoproteins and
16 incidence of non-insulin-dependent diabetes mellitus in Pima Indians:
17 protective effect of HDL cholesterol in women. *Atherosclerosis*
18 1997;**128**(1):113-9
19 10
20 11 32. Sierra-Johnson J, Romero-Corral A, Somers VK, et al. ApoB/apoA-I ratio: an
21 independent predictor of insulin resistance in US non-diabetic subjects. *Eur*
22 *Heart J* 2007;**28**(21):2637-43 doi: 10.1093/eurheartj/ehm360[published Online
23 First: Epub Date]].
24 13
25 14 33. Ying X, Qian Y, Jiang Y, Jiang Z, Song Z, Zhao C. Association of the
26 apolipoprotein B/apolipoprotein A-I ratio and low-density lipoprotein
27 cholesterol with insulin resistance in a Chinese population with abdominal
28 obesity. *Acta Diabetol* 2012;**49**(6):465-72 doi:
29 10.1007/s00592-012-0419-9[published Online First: Epub Date]].
30 17
31 34. Sniderman AD, Faraj M. Apolipoprotein B, apolipoprotein A-I, insulin resistance
32 and the metabolic syndrome. *Curr Opin Lipidol* 2007;**18**(6):633-7 doi:
33 10.1097/MOL.0b013e3282f0dd33[published Online First: Epub Date]].
34 18
35 19 35. Hogue JC, Lamarche B, Tremblay AJ, Bergeron J, Gagne C, Couture P. Evidence
36 of increased secretion of apolipoprotein B-48-containing lipoproteins in
37 subjects with type 2 diabetes. *J Lipid Res* 2007;**48**(6):1336-42 doi:
38 10.1194/jlr.M600548-JLR200[published Online First: Epub Date]].
39 22
40 41 36. Duez H, Lamarche B, Uffelman KD, Valero R, Cohn JS, Lewis GF.
42 Hyperinsulinemia is associated with increased production rate of intestinal
43 apolipoprotein B-48-containing lipoproteins in humans. *Arterioscler Thromb*
44 *Vasc Biol* 2006;**26**(6):1357-63 doi:
45 10.1161/01.ATV.0000222015.76038.14[published Online First: Epub Date]].
46 29
47 30
48 31
49 32
50 33
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1 37. Anagnostis P, Stevenson JC, Crook D, Johnston DG, Godsland IF. Effects of
4 2 gender, age and menopausal status on serum apolipoprotein concentrations.
5 3 Clin Endocrinol (Oxf) 2016 doi: 10.1111/cen.13085[published Online First:
6 4 Epub Date]].
7
8 38. Li Z, McNamara JR, Fruchart JC, et al. Effects of gender and menopausal status
9 5 on plasma lipoprotein subspecies and particle sizes. J Lipid Res
10 6 1996;**37**(9):1886-96
11 7
12 39. Kuller LH, Gutai JP, Meilahn E, Matthews KA, Plantinga P. Relationship of
13 8 endogenous sex steroid hormones to lipids and apoproteins in postmenopausal
14 9 women. Arteriosclerosis 1990;**10**(6):1058-66
15 10
16 40. Soler JT, Folsom AR, Kaye SA, Prineas RJ. Associations of abdominal adiposity,
17 11 fasting insulin, sex hormone binding globulin, and estrone with lipids and
18 12 lipoproteins in post-menopausal women. Atherosclerosis 1989;**79**(1):21-7
19 13
20 41. Pirwany IR, Fleming R, Greer IA, Packard CJ, Sattar N. Lipids and lipoprotein
21 14 subfractions in women with PCOS: relationship to metabolic and endocrine
22 15 parameters. Clin Endocrinol (Oxf) 2001;**54**(4):447-53
23 16
24 42. Rexrode KM, Manson JE, Lee IM, et al. Sex hormone levels and risk of
25 17 cardiovascular events in postmenopausal women. Circulation
26 18 2003;**108**(14):1688-93 doi: 10.1161/01.CIR.0000091114.36254.F3[published
27 19 Online First: Epub Date]].
28 20
29 43. Mudali S, Dobs AS, Ding J, et al. Endogenous postmenopausal hormones and
30 21 serum lipids: the atherosclerosis risk in communities study. J Clin Endocrinol
31 22 Metab 2005;**90**(2):1202-9 doi: 10.1210/jc.2004-0744[published Online First:
32 23 Epub Date]].
33 24
34 44. Bernini GP, Sgro M, Moretti A, et al. Endogenous androgens and carotid
35 25 intimal-medial thickness in women. J Clin Endocrinol Metab
36 26 1999;**84**(6):2008-12 doi: 10.1210/jcem.84.6.5824[published Online First:
37 27 Epub Date]].
38 28
39 45. Armeni E, Lambrinoudaki I, Ceausu I, et al. Maintaining postreproductive health:
40 29 A care pathway from the European Menopause and Andropause Society
41 30 (EMAS). Maturitas 2016;**89**:63-72 doi:
42 31 10.1016/j.maturitas.2016.04.013[published Online First: Epub Date]].
43 32
44 46. Abootalebi M, Kargar M, Jahanbin I, Sharifi AA, Sharafi Z. Knowledge and
45 33
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Attitude about Andropause Among General Physicians in Shiraz, Iran 2014.
2 Int J Community Based Nurs Midwifery 2016;4(1):27-35

3

4 **Figure legend**

5 **Fig 1 Prevalence of pre-diabetes and diabetes according to tertiles of**
6 **ApoB/ApoA-I ratio**

7 The numbers above the bars mean the prevalence of each outcome, respectively.

8 T1: tertile 1; T2: tertile 2; T3: tertile.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1

2

For peer review only

1

Table 1 Characteristics of participants according to glucose status and gender

	NGT			Pre-diabetes			Diabetes			P1	P2	P3
	Total	Men	Women	Total	Men	Women	Total	Men	Women			
Number	267	99	168	240	90	150	222	75	147	NS	NS	NS
Age	51.0	51.0	51.0	56.0	56.0	56.0	56.0	58.0	56.0	<0.001	<0.001	NS
(years)	(41.0,57.0)	(41.5,57.5)	(40.0,57.0)	(45.0,61.0)	(44.0,59.0)	(47.0,62.0)	(46.0,60.0)	(46.0, 61.5)	(46.0,59.5)			
SBP	114.0	114.0	110.0	121.0	116.0	121.0*	121.0	119.0	120.0	<0.001	<0.001	NS
(mmHg)	(113.0,116.0)	(102.0,127.0)	(102.0,120.5)	(119.0,123.0)	(110.0,131.0)	(114.0,132.0)	(119.0,123.0)	(113.0,129.5)	(110.0,130.5)			
DBP	74.0	72.0	74.0	77.0	78.0	78.0	80.0	79.0	79.0	<0.001	<0.001	0.005
(mmHg)	(73.0,75.0)	(68.0,79.0)	(69.0,80.0)	(76.0,78.0)	(72.0,83.0)	(74.0,82.0)	(78.0,81.0)	(73.5,82.0)	(75.5,85.5)			
BMI	23.03	23.11	23.06	23.92	24.12	23.64	25.09	27.67	23.37**	0.005	<0.001	<0.001

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

	(22.60,23.46)	(21.32,25.15)	(19.78,24.92)	(23.47,24.37)	(21.21,27.46)	(21.79,26.33)	(24.61,25.55)	(24.23,29.45)	(21.94,26.38)			
WHR	0.86	0.88	0.85*	0.89	0.89	0.89	0.90	0.91	0.90*	<0.001	<0.001	0.001
	(0.85,0.87)	(0.82,0.91)	(0.81,0.90)	(0.88,0.89)	(0.84,0.93)	(0.86,0.92)	(0.90,0.91)	(0.89,0.94)	(0.87,0.93)			
FPG	4.98	4.98	5.01	5.57	5.44	5.60	7.31	7.33	7.15**	<0.001	<0.001	<0.001
(mmol/L)	(4.87,5.09)	(4.65,5.25)	(4.75,5.35)	(5.46,5.69)	(4.92,5.97)	(5.04,6.11)	(7.19,7.43)	(7.16,8.06)	(5.73,7.87)			
2hPG	6.01	5.88	6.05	9.29	9.19	9.36	13.95	12.99	13.07	<0.001	<0.001	<0.001
(mmol/L)	(5.77,6.26)	(5.30,6.55)	(5.19,6.83)	(9.03,9.54)	(8.51,9.85)	(8.58,10.19)	(13.68,14.21)	(12.23,14.76)	(11.92,14.73)			
FINS	13.73	12.27	11.98	14.70	11.75	12.06	15.38	14.77	14.19	NS	0.014	NS
(µIU/L)	(12.85,14.61)	(9.51,16.90)	(8.76,20.11)	(13.78,15.61)	(10.59,17.71)	(10.74,18.71)	(14.42,16.33)	(10.80,20.03)	(9.82,18.29)			
2hINS	64.18	42.98	55.13	80.05	75.27	71.97	71.23	65.53	63.75*	0.001	NS	NS
(µIU/L)	(57.49,70.87)	(24.02,87.40)	(35.57,71.38)	(73.08,87.02)	(41.60,119.56)	(48.35,103.81)	(63.97,78.49)	(24.57,90.22)	(34.21,110.37)			
HbA1c	5.5	5.5	5.6	5.8	5.8	5.9*	6.9	6.9	6.7	<0.001	<0.001	<0.001
(%)	(5.4,5.6)	(5.2,5.7)	(5.3,5.8)	(5.7,5.9)	(5.5,6.0)	(5.6,6.1)	(6.8,7.0)	(6.6,7.3)	(6.0,7.4)			

HOMA-IR	3.07	2.63	2.67	3.72	2.93	3.28	5.04	4.82	4.18	0.001	<0.001	<0.001
	(2.81,3.33)	(2.01,3.86)	(1.95,4.60)	(3.46,3.99)	(2.27,4.18)	(2.58,4.58)	(4.76,5.32)	(3.46,7.29)	(3.15,5.85)			
HOMA-β	218.63	185.08	161.87	154.67	123.17	122.29	93.41	77.45	74.54	<0.001	<0.001	<0.001
	(203.73,233.53)	(136.51,246.24)	(124.18,257.26)	(139.14,170.19)	(94.47,185.50)	(87.07,186.75)	(77.24,109.58)	(58.17,88.08)	(55.07,112.40)			
TG	1.50	1.23	1.15	1.77	1.50	1.68	2.72	2.55	2.44	0.012	<0.001	<0.001
(mmol/L)	(1.36,1.65)	(0.77,1.70)	(0.77,1.77)	(1.62,1.92)	(1.06,1.99)	(1.09,2.24)	(2.56,2.88)	(1.73,4.14)	(1.69,3.50)			
TC	5.02	4.94	5.02*	5.13	5.15	5.27	5.64	5.47	5.90	NS	<0.001	<0.001
(mmol/L)	(4.92,5.12)	(4.67,5.20)	(4.67,5.40)	(5.03,5.23)	(4.31,5.78)	(4.66,5.55)	(5.53,5.75)	(5.13,6.18)	(4.93,6.29)			
HDL-C	1.48	1.43	1.45	1.34	1.30	1.29	1.23	1.12	1.28*	<0.001	<0.001	<0.001
(mmol/L)	(1.44,1.51)	(1.19,1.69)	(1.24,1.68)	(1.31,1.38)	(1.14,1.48)	(1.15,1.46)	(1.19,1.27)	(1.09,1.28)	(1.07,1.38)			
LDL-C	3.03	2.84	3.12	3.05	2.83	3.08	3.37	3.50	3.36	NS	<0.001	<0.001
(mmol/L)	(2.95,3.12)	(2.58,3.29)	(2.58,3.45)	(2.96,3.14)	(2.60,3.78)	(2.76,3.54)	(3.28,3.47)	(2.88,3.69)	(3.02,4.18)			
ApoA-I	1.48	1.43	1.45	1.39	1.40	1.34	1.33	1.36	1.31	<0.001	<0.001	0.005

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

(g/L)	(1.45,1.51)	(1.31,1.68)	(1.28,1.63)	(1.36,1.43)	(1.26,1.56)	(1.25,1.52)	(1.29,1.36)	(1.22,1.38)	(1.17,1.42)			
ApoB	0.84	0.80	0.84	0.91	0.90	0.97**	0.97	0.97	1.05**	<0.001	<0.001	0.001
(g/L)	(0.81,0.86)	(0.68,0.97)	(0.68,0.97)	(0.88,0.93)	(0.70,0.98)	(0.84,1.03)	(0.94,1.00)	(0.80,1.03)	(0.87,1.17)			
ApoB/Apo	0.60	0.55	0.56	0.67	0.66	0.74**	0.76	0.71	0.78**	<0.001	<0.001	<0.001
A-I ratio	(0.57,0.62)	(0.42,0.72)	(0.44,0.72)	(0.64,0.70)	(0.48,0.77)	(0.56,0.81)	(0.73,0.78)	(0.60,0.82)	(0.68,0.94)			

1 Data were expressed as medians (interquartile ranges 25-75%).

2 SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; WHR: waist to hip ratio; FPG: fasting plasma glucose; 2hPG:

3 2 hour postload plasma glucose; FINS: fasting serum insulin; 2hINS: 2 hour postload serum insulin; HbA1c: glycated hemoglobin A1c; HOMA-IR:

4 homeostatic model assessment of insulin resistance; HOMA- β : homeostatic model assessment of β -cell function; TG: triglyceride; TC: total

5 cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; ApoA-I: apolipoprotein A-I; ApoB:

6 apolipoprotein B.

7 *P1*: NGT versus pre-diabetic group, *P2*: NGT versus diabetic group, *P3*: pre-diabetic versus diabetic group

8 * $P < 0.05$, ** $P < 0.01$ means the gender difference in each group

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

1 Comparisons among NGT, pre-diabetic and diabetic groups were performed after adjusting for age

For peer review only

1

Table 2 Partial correlation coefficients of ApoB/ApoA-I ratio with lipid profiles and glycometabolism-related traits

	NGT		Pre-diabetes		Diabetes	
	Men	Women	Men	Women	Men	Women
TG (mmol/L)	0.500 ^{***}	0.474 ^{***}	0.560 ^{***}	0.570 ^{***}	0.503 ^{***}	0.654 ^{***}
TC (mmol/L)	0.410 ^{***}	0.350 ^{***}	0.331 ^{**}	0.271 ^{**}	0.292 [*]	0.648 ^{***}
HDL (mmol/L)	-0.835 ^{***}	-0.727 ^{***}	-0.614 ^{***}	-0.563 ^{***}	-0.337 ^{**}	-0.721 ^{***}
LDL (mmol/L)	0.652 ^{***}	0.597 ^{***}	0.433 ^{***}	0.228 ^{**}	0.427 ^{***}	0.767 ^{***}
FPG (mmol/L)	0.340 ^{**}	0.261 ^{**}	0.432 ^{***}	0.296 ^{***}	0.675 ^{***}	0.471 ^{***}
2hPG (mmol/L)	0.550 ^{***}	0.277 ^{***}	0.198	0.287 ^{***}	0.300 [*]	0.162
FINS (μIU/mL)	0.281 ^{**}	0.195 [*]	0.370 ^{***}	0.122	0.581 ^{***}	0.463 ^{***}
2hINS (μIU/mL)	0.279 ^{**}	0.286 ^{***}	0.696 ^{***}	0.182 [*]	0.109	0.172 [*]
HbA1C (%)	0.253 [*]	0.254 ^{**}	0.274 [*]	0.213 [*]	0.265 [*]	0.278 ^{**}
HOMA-IR	0.326 ^{**}	0.225 ^{**}	0.427 ^{***}	0.175 [*]	0.677 ^{***}	0.584 ^{***}
HOMA-β	-0.007	-0.016	0.014	-0.084	0.208	-0.007

2 Data were analyzed after adjusting for age, SBP and DBP. Variables with skewed
3 distributions were log-transformed before statistical analysis.

4 * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$

5

6

7

Table 3. The risk of pre-diabetes and Type 2 diabetes according to tertiles of ApoB/ApoA-I ratio in men

		T1	T2	T3
		(0-0.5703)	(0.5704-0.7723)	(≥0.7724)
Pre-diabetes	n, cases/participants	32/102	34/90	24/72
	Model 1	1	1.602 (1.080, 2.122)*	1.427 (0.897, 1.997)
	Model 2	1	1.381 (0.868, 1.943)	1.160 (0.670, 1.758)
	Model 3	1	1.327 (0.813, 1.905)	1.113 (0.599, 1.769)
Type 2 Diabetes	n, cases/participants	18/102	31/90	26/72
	Model 1	1	2.461 (1.506, 3.510)**	2.394 (1.422, 3.485)**
	Model 2	1	2.035 (1.152, 3.126)*	1.901 (1.034, 3.022)*
	Model 3	1	1.643 (0.865, 2.723)	1.074 (0.481, 2.100)

1 Data are relative ratios (RR), 95% confidential intervals (CI).

2 Model 1: unadjusted

3 Model 2: adjusted for age, SBP, DBP

4 Model 3: adjusted for Model 2+ TC

5 * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$

6

7

8

9

10

11

12

13

14

Table 4. The risk of pre-diabetes and Type 2 diabetes according to tertiles of ApoB/ApoA-I ratio in women

		T1	T2	T3
		(0-0.5703)	(0.5704-0.7723)	(≥0.7724)
Pre-diabetes	n, cases/participants	40/141	48/153	62/171
	Model 1	1	1.568 (1.119, 2.044)**	2.221 (1.728, 2.647)***
	Model 2	1	1.317 (0.876, 1.826)	2.009 (1.472, 2.503)***
	Model 3	1	1.478 (0.898, 2.131)	2.186 (1.376, 2.842)**
Type 2 Diabetes	n, cases/participants	15/141	54/153	78/171
	Model 1	1	3.943 (2.540, 5.500)***	5.940 (4.353, 7.272)***
	Model 2	1	3.405 (2.078, 5.001)***	5.439 (3.767, 6.939)***
	Model 3	1	3.115 (1.598, 5.126)**	3.651 (1.685, 6.099)**


1 Data are relative ratios (RR), 95% confidential intervals (CI).

2 Model 1: unadjusted

3 Model 2: adjusted for age, SBP, DBP, BMI

4 Model 3: adjusted for Model 2+TC, TG, HDL-C, LDL-C

5 * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$



80x26mm (600 x 600 DPI)

peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cross-sectional studies

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	1-2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	4-5
Methods			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7
Bias	9	Describe any efforts to address potential sources of bias	5-8
Study size	10	Explain how the study size was arrived at	5-6
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(d) If applicable, describe analytical methods taking account of sampling strategy	8
		(e) Describe any sensitivity analyses	8
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9
		(b) Give reasons for non-participation at each stage	9
		(c) Consider use of a flow diagram	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9
		(b) Indicate number of participants with missing data for each variable of interest	9
Outcome data	15*	Report numbers of outcome events or summary measures	9
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-11
		(b) Report category boundaries when continuous variables were categorized	9
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	9-10
Discussion			
Key results	18	Summarise key results with reference to study objectives	11-12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	16
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-16
Generalisability	21	Discuss the generalisability (external validity) of the study results	16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.